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Tuberculosis (TB) is a communicable disease caused by an infectious bacterial pathogen 
called Mycobacterium tuberculosis (Mtb), which is acquired through the inhalation of 
bacilli-containing droplets. With the emergence of resistant strains (multidrug-resistant 
TB (MDR-TB), extensively drug-resistant TB (XDR-TB) and totally drug-resistant TB 
(TDR-TB)), co-infection with human immunodeficiency virus (HIV), the existence of 
latent TB infection (LTBI) and the extensive treatment regimen resulting in poor patient 
compliance, there is therefore a need to develop novel antimycobacterial agents to 
address these limitations. Within this context, 2-aminoquinazolinone compounds with 
potent antimycobacterial activity were previously identified.  Poor solubility was 
recognized as a major issue requiring improvement. To this end, structure-activity 
relationship (SAR) studies were performed around the 2-aminoquinazolinone core in 
order to optimize these potential antimycobacterial agents with respect to solubility and 
potency. Various structural modification strategies aimed at improving solubility were 
explored.  These included reducing lipophilicity by introduction of hydrophilic 
substituents as well as disruption of molecular planarity and/or symmetry of the 
molecule through removal of aromaticity or increase in the dihedral angle.  
Several analogues displayed promising in vitro antimycobacterial activity against the 
H37Rv strain of Mtb in glycerol-containing media along with high microsomal metabolic 
stability. However, the same compounds, with the exception of one phenolic 
intermediate, were inactive in subsequent assay media that did not contain glycerol as a 
carbon source. On this basis, the mechanism of action of the 2-aminoquinazolinone 
series was postulated to be glycerol-dependent. On the other hand, structural 
modifications, guided by solubility-enhancing strategies, generally resulted in 
compounds with markedly improved solubility. Saturated ring analogues displayed the 
most improvement in solubility, which was also reflected in the lower melting points. 
Additionally, the relationships between solubility and physicochemical parameters 
(ClogP, tPSA and melting point) were deduced. Melting point was found to be the most 
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CHAPTER 1:  INTRODUCTION AND LITERATURE REVIEW 
1.1. TUBERCULOSIS 
1.1.1. EPIDEMIOLOGY AND AETIOLOGY 
Tuberculosis (TB) is a communicable disease caused by an infectious bacterial pathogen 
called Mycobacterium tuberculosis (Mtb), which typically replicates in the lungs 
(pulmonary TB) but can affect other areas too (extrapulmonary TB).1 According to the 
World Health Organization (WHO), 10.4 million people developed TB in 2015 (Figure 1) 
with 1.8 million deaths occurring worldwide making it the leading cause of death from a 
curable infectious disease. Six countries, India, Indonesia, China, Nigeria, Pakistan and 
South Africa accounted for 60% of new cases. TB has thus been recognized as one of 
















Figure 1: Pictorial diagram representing the annual number of incident TB cases relative to 
population size (incidence rate) for 2015.1  
A variety of species of mycobacteria that are related to Mtb, which includes M. bovis, M. 
tuberculosis, M. africanum, M. microti and M. canettii are referred to as the mycobacterial 
complex.3 Mycobacteria appear as slightly curved or straight rods that are 1 – 4 μm in 
length and 0.3 – 0.6 μm in width and are characterized as non-sporulating, non-motile, 
weakly gram-positive and acid-fast bacilli. The waxy cell wall of mycobacteria has many 
unique characteristics that enable survival in its host such as hydrophobicity, resistance 
to drying, acid-fastness against staining and resistance to varying acidic/alkaline 
environments.4  
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Mtb infection is acquired through the inhalation of bacilli-containing droplets, mainly 
from patients with active pulmonary TB, and develops as a consequence of failed 
immune regulation in the host. However, the majority of people infected with Mtb 
acquire it as an asymptomatic latent TB infection (LTBI). Approximately 2-3 billion 
people have LTBI and are therefore at risk of reactivation of the disease, with 10% of 
those progressing into active TB.5,6 This can be prevented through effective treatment. 
The development of novel vaccines that may prevent TB disease reactivation by 
containing the pathogen in a latent state in LTBI persons is being investigated. About 13 
of these vaccine candidates have entered clinical trials in the past few years.1 A 
shortcoming of these vaccines is that they do not eradicate the pathogen but rather 
prevent or delay the reactivation of the dormant infection.3  
The probability of developing TB is much higher among people infected with human 
immunodeficiency virus (HIV) whereby TB is the leading cause of morbidity and 
mortality among HIV-infected people. This could be attributed to the enhancement of 
the HIV replication process by the host’s immune response to Mtb and possibly leading 
to acceleration of the natural progression of the HIV infection. 1.2 Million people of the 
10.4 million who developed TB in 2015 were HIV positive resulting in 400 000 deaths. 
The African region accounts for the highest proportion of HIV-positive TB cases (31%) 
and exceeds 50% in parts of Southern Africa (Figure 2), as a result of the TB epidemic 








Figure 2: Pictorial diagram representing the proportion of TB cases coinfected with HIV.1  
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1.1.2. CURRENT TREATMENT 
The current anti-TB drugs can be divided into first-line drugs and second-line drugs. 
First-line drugs include isoniazid (INH), rifampicin (RIF), ethambutol (EMB), 
pyrazinamide (PZA) and streptomycin (Figure 3). Second-line drugs include injectables 
such as amikacin, kanamycin, capreomycin; ciprofloxacin and ofloxacin as 
fluoroquinolones; as well as ethionamide, cycloserine and p-aminosalicylic acid (Figure 














Figure 3: Chemical structures of first-line anti-TB drugs. 
The current chemotherapy regime outlined in Figure 5 involves a 2 – 4 month intensive 
phase whereby the first-line drugs are administered followed by a continuation phase 
for 4 – 18 months with isoniazid and rifampicin in combination with some second-line 
drugs, should they be required.5,8 The WHO recommended a TB control strategy 
involving Directly Observed Therapy Short Course (DOTS) wherein the above treatment 
regimen is directly observed by a healthcare worker for at least the first 2 months of 































































































































































































Challenges of the current therapy include drug intolerance and toxicities, 
pharmacokinetics (PK), patient adherence and drug-drug interactions, specifically with 
antiretroviral therapy (ART) drugs in patients co-infected with TB and HIV.5 The 
prolonged treatment duration could possibly be attributed to the presence of 
subpopulations of bacteria that are non-replicating (NR-Mtb) and this contributes to 
poor patient compliance, high incidence of side effects and the emergence of drug 
resistant Mtb strains.9 These strains have been termed multidrug-resistant TB (MDR-
TB), extensively drug-resistant TB (XDR-TB) and totally drug-resistant TB (TDR-TB).10 
MDR-TB occurs when the strain is resistant to isoniazid and rifampicin and accounted 
for approximately half a million new cases to the total TB incidences in 2015, 9.5% of 
which had XDR-TB.1 XDR-TB occurs when the strain is resistant to isoniazid and 
rifampicin as well as to any of the aforementioned fluoroquinolones and to at least one 
of three of the second-line injectable drugs, whilst strains that are resistant to all 
available first-line and second-line TB drugs are termed TDR-TB.2,5  
Treatment for MDR-TB ideally requires individualized programs based on in vitro drug-
susceptibility testing (DST) for each patient, resulting in a more complicated and time-
consuming treatment with increased patient compliance. MDR-TB patients should 
undergo the intensive phase for 8 months with incorporation of at least four of the 
second-line drugs in combination with pyrazinamide.5,11 The total treatment duration 
amounts to 20 months in patients with no previous treatment and 28 months in those 
who have had previous treatment  with patients being monitored using sputum smear 
microscopy as well as culture. ART is recommended for all patients with HIV and drug-
resistant TB requiring second-line anti-TB drugs irrespective of CD4 cell count, as early 
as possible (first 8 weeks) following initiation of anti-TB treatment.5,11 
1.1.3. ADVANCES IN THE DEVELOPMENT OF NEW ANTI-TB DRUGS 
With the emergence of resistant strains, co-infection with HIV, the existence of LTBI and 
the extensive treatment regimen; the future of drug design in the development of new 
anti-TB drugs should aim to: 
- Shorten the duration of treatment by developing more potent drugs than existing 
drugs 
- Target MDR and XDR strains of Mtb5 
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- Simplify treatment by reducing the pill burden and dosing frequency 
- Decrease drug-drug interactions with no antagonism to other TB drugs and ARTs 
- Kill Mtb in its different physiological states, including LTBI. 12,13 
Many drug candidates currently in clinical trials are drugs that were developed to treat 
other infectious diseases and have since been repurposed for the treatment of TB 
(Figure 6).5 Specifically, some compounds that have been repurposed for TB include the 
fluoroquinolones, gatifloxacin and moxifloxacin, which are currently in phase III clinical 
trials, and were originally used in the treatment of respiratory tract infections. 
Metronidazole is a nitromidazole that is used in the treatment of infections caused by 
anaerobic bacteria and protozoa and is now in phase II clinical trials as a potential anti-
TB drug. Additionally, the oxazolidinone, linezolid was previously used to treat 
infections caused by gram-positive pathogens and has since been repurposed for TB and 













Figure 6: Chemical structures of various repurposed drugs for the use in TB treatment. 
A number of new drug candidates based on known chemotypes have advanced to 
clinical trials (Figure 8). Examples of such are depicted in Figure 7 and include other 
oxazolidinone derivatives, AZD-5847 and sutezolid (PNU-100480) which are in phase II 
clinical trials. Additional phase II drug candidates include SQ-109, an analog of 





























nitroimidazole derivative.14,15 However, the first nitroimidazole-type compound to enter 
clinical trials was delamanid (OPC-67683), which is now in phase III along with the 
diarylquinoline bedaquiline (TMC-207). 15,16  
For the first time in more than 40 years, the US Food and Drug Administration (FDA) 
and European Medicines Agency (EMA) have conditionally approved bedaquiline and 
delamanid as anti-TB drugs, specifically for the treatment of MDR-TB.16,17 The TB 
Alliance have partnered with Janssen Pharmaceutica and sites in South Africa to launch 
the Nix-TB trial, the first clinical trial study for XDR-TB. Nix-TB was launched in March 
2015 and is aimed at evaluating the efficacy, safety, tolerability and PK of 6 months 












































































Figure 8: Global TB drug pipeline summarizing current clinical trial candidates.19 
These advances in anti-TB drugs are a promising development but there is still an 
ongoing need to develop potent drugs that can combat the various limitations of current 
regimens. 
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1.2. PROPERTIES OF DRUG CANDIDATES IN DRUG DISCOVERY 
There are a number of physiological barriers that exist in vivo, which reduce the amount 
of dosed compound that reaches the target. Therefore, a drug candidate should possess 
properties that enable good absorption, distribution, metabolism, elimination (ADME) 
properties and low toxicity in order to reach these targets. Good absorption is attributed 
to dissolution rate and solubility in the gastrointestinal tract. First pass metabolism 
occurs here followed by metabolism in the liver. Distribution happens when the 
compound permeates into the tissues from the blood capillaries, with elimination 
occurring simultaneously by removal of the compound from the bloodstream by the 
liver and kidneys.20,21 
Various properties determine the effectiveness of a drug candidate. In order for a drug-
like compound to survive through the completion of human clinical trials, this 
compound would need to posses sufficiently acceptable ADME and toxicity properties. 
Improvement of these properties early on in drug discovery is important in saving time 
and resources on failed drug candidates. Efficient ADME processes can be determined by 
physicochemical (solubility, permeability, lipophilicity, chemical stability), PK 
(clearance, half-life, bioavailability, drug-drug interactions, LD50) and biochemical 
(metabolism, protein and tissue binding, and transport) properties.22,23 Improvement of 
these properties is most often performed by modification of the chemical structure, 
usually at sites in the molecule which have been shown by structure-activity 
relationship (SAR) studies to not be crucial for therapeutic target binding.20  
These various properties are most often influenced by structural properties such as 
hydrogen bonding, lipophilicity, molecular weight, pKa, polar surface area (PSA), shape 
and reactivity. Therefore, modifications of these structural parameters will allow for 
improved ADME properties. In this regard, a set of guidelines, known as the Lipinski’s 
rule of 5 (RO5), was established. The RO5 states that drug likeness is more likely when 
the number of hydrogen-bond donors (HBD) (sum of OH and NH) is < 5; the number of 
hydrogen-bond acceptors (HBA) (sum of O and N atoms) is < 10; the molecular weight 
(MW) is < 500 Daltons (Da); and when ClogP (the calculated 1-octanol/water partition 
coefficient) is < 5.20,24  
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Optimization of the physicochemical, PK and biochemical characteristics using these 
various strategies and guidelines should enable improved ADME processes to allow for 
the synthesis of effective potential drug candidates active in vivo. 
1.2.1. SOLUBILITY IMPROVEMENT STRATEGIES 
Poor absorption of drug candidates can result due to poor solubility despite the 
possibility of having a high permeation rate.25 Solubility is the maximum dissolved 
concentration under given solution conditions and is a major determinant of intestinal 
absorption and oral bioavailability and therefore plays a major role in the effectiveness 
of the drug.20 Many drug development failures are a result of poor solubility.25  
There are a variety of methods that can be implemented to improve the solubility of a 
compound. This could be through physical methods such as utilizing different 
polymorphs, solid dispersion of hydrophobic drugs with a hydrophilic carrier or 
through the formation of salts.20,26,27 The application of supramolecular techniques for 
instance, the formation of inclusion complexes (eg. cyclodextrins) or cocrystal 
formation, can be formulated to provide a more soluble drug.26,27 
Additionally, various chemical modification strategies enable solubility improvement. 
Some of the strategies involve the addition of an ionizable group, reducing ClogP 
(lipophilicity), addition of hydrogen-bonding, adding a polar group, reducing the 
molecular weight, constructing a prodrug, or disruption of molecular planarity and 
symmetry to reduce crystal packing.20  
The addition of ionizable groups such as basic amines and carboxylic acids results in 
improved solubility, as ionized molecules are more soluble in aqueous media than the 
neutral molecule as they are more polar.20 An example of such is the incorporation of an 
amine side chain onto the antimalarial agent artemisinin, which resulted in enhanced 
solubility (Figure 9).28 Furthermore, the protease inhibitor L-685,434 possessed good 
potency in vitro but lacked in vivo activity, owing to poor solubility. Introduction of an 
ionizable centre resulted in improved solubility, allowing for better absorption and thus 















Figure 9: Examples of structures incorporating ionizable groups to improve solubility. 
A general approach to improving solubility is through the reduction of lipophilicity since 
the aqueous solubility of a molecule is generally dependent on their hydrophobicity 





Therefore, as solubility in aqueous media increases, the logP value decreases. This can 
be accomplished by introducing hydrophilic groups. Hydrophilic groups may, however, 
interfere with the necessary hydrophobic target protein – drug interactions.25 Examples 
of hydrophilic substituents are represented in the two left-hand side (LHS) quadrants   
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Introducing water solubilizing H-bonding groups, HBD and HBA, such as hydroxyl or 
amino groups has been shown to improve solubility. For example studies reported by Le 
Manach et al. focused on the synthesis and evaluation of antiplasmodial compounds, 
specifically on the improvement of solubility and efficacy properties of the lead 
compound, 3,6-diarylimidazopyridazine (A) (Figure 11). Substitution of one of the 
sulfone moieties for a more H-bonding hydroxyl-containing amide (B) or a piperazine 
sulfonamide group (C) resulted in enhanced solubility whilst maintaining activity. 
Replacement of the sulfone for the more strongly H-bonding sulfoxide substituent as in 














Figure 11: Examples of introducing various H-bonding groups to improve solubility of lead compound 
A.30 
 
The solubility of a solid solute in water depends on the crystallinity of the solute and the 
ability of the solute to interact with water. Therefore disruption of crystal packing would 
be a method for improving aqueous solubility. However, few modifications based on 
crystal packing have been reported. What is known though is that melting point is 
related to crystal lattice and crystal packing energies and that molecular symmetry and 
planarity are known to influence crystal packing. Therefore, upon disruption of the 
molecular planarity, a decrease in the efficiency of crystal packing would be expected 
resulting in a decrease of the melting point, which provides a reasonable strategy to 




























thumb says that symmetrical molecules pack in a three-dimensional periodic lattice 
more easily than less symmetrical ones therefore forming more stable, higher-melting 
and less soluble crystals.”25 
Various strategies for the reduction of crystal packing can be achieved either by removal 
of aromaticity, increasing the dihedral angle, introduction of substituents into the 
benzylic position and/or by twisting of fused rings. Disruption of molecular symmetry 
enables an increase in aqueous solubility without an increase of molecular weight, 
which could negatively affect PK.25 
Removal of aromaticity results in distortion of the ring conformation away from 
planarity therefore disturbing the crystal-stacking ability of the compound. For example, 
Wang et al. identified vanilloid receptor 1 (TRPV1) antagonists (E) that were 
thermodynamically insoluble and therefore introduced partial saturation to the 4-
(trifluoromethyl)phenyl ring substituent (F) to reduce structural planarity (Figure 12).31  
The new derivative depicted in Figure 12 (F) showed a 13-fold improvement in 
solubility, but a decrease in potency was observed. Looking at the calculated 
parameters, a decrease in melting point suggests solubility improvement can be partly 
attributed to the disruption of planarity as well as to increased hydrophilicity (lower 








Figure 12: Example of removal of aromaticity to enhance solubility of a TRPV1 antagonist. 
Little is known about the effect of increased dihedral angles on solubility but an example 
is illustrated in the case of polychlorinated biphenyls. It was found that ortho-
substituted biphenyls, which have larger dihedral angles, showed increased solubility. 
Specifically, ortho derivative 2,2’-dichlorobiphenyl (G) exhibited a greater aqueous 
 14 
solubility of 900 μg/mL than 2,4’-dichlorobiphenyl (H) and 4-chlorobiphenyl (I), which 
obtained solubility values of 637 μg/mL and 400 μg/mL, respectively (Figure 13).25,32 
The dihedral angle is a convenient numerical parameter that can be obtained by 
calculation or by X-ray crystal structure analysis and therefore makes it a suitable 





Figure 13: Examples of polychlorinated biphenyls to show the effect of dihedral angles on solubility. 
 
This research project partly focuses on reduction of lipophilicity by means of 
introducing hydrophilic substituents as well as the disruption of molecular planarity and 
symmetry through removing aromaticity and increasing dihedral angles to improve 
solubility. Incorporation of a combination of approaches was also explored. 
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1.3.  PHARMACOLOGICAL ACTIVITY OF AMINOQUINAZOLINONES 
2-Aminoquinazolin-4(3H)-ones are derived from a class of compounds called 
quinazolinones. Quinazolinones have been extensively explored in a variety of 
therapeutic areas, with studies showing antitumor,33 antifungal,34 antibacterial,35 
anticancer,36,37 antimalarial,38 antihypertensive,39 anti-inflammatory,40 antimicrobial41–
43 and sedative hypnotic44 effects of these compounds (Figure 14). On the other hand, 
literature on the 2-aminoquinazolin-4(3H)-ones derivatives as therapeutic entities is 
















Figure 14: Examples of some quinazolinone scaffolds with various therapeutic effects. 
 
However, recently Lievers et al. identified 2-aminoquinazolinone (J) in Figure 15, 
through various optimizational strategies, as a potent inhibitor of Hepatitis C virus 
(HCV) replication in vitro as a result of J inhibiting the lipid kinase P14K111α, a host 
cellular protein, which is essential for HCV replication. Inhibition of this protein will halt 



































On the other hand, research by Deuschle and colleagues established various 
aminoquinazolinone derivatives possessing partial agonistic properties upon binding to 
liver X receptors (LXR). LXRs play an important role in the control of cholesterol 
homeostasis in intestinal mucosa cells and macrophages. Therefore, these LXR nuclear 
receptor protein-binding compounds (K) were patented towards further development 
as treatments for cholesterol-related conditions or diseases and/or lipid-associated 
disorders (Figure 15).46 
Recently, Jirgensons and coworkers patented 2-aminoquinazolin-4(3H)-one derivatives 
containing a tetrahydrofuran moiety in the 3-position and a 7-phenyl substituent as a 
novel class of nonpeptidomimetic inhibitors of malarial aspartic proteases, specifically 
digestive plasmepsins I, II and IV. These plasmepsins are involved in the degradation of 
haemoglobin to amino acids making them promising targets for antimalarial drugs. 
Compound L was discovered using nuclear magnetic resonance (NMR) spectroscopy-










Figure 15: Representative 2-aminoquinazolin-4(3H)-one derivatives with therapeutic effects. 
Within the context of TB, some research has explored the incorporation of 
quinazolinones as anti-TB agents (Figure 16). Particularly, Pattan and co-workers 
identified various N-3(4-(4-chlorophenylthiazole-2-yl)-(2-(amino)methyl)-quinazolin-
4(3H)-one derivatives (M) (Figure 16), as potential growth inhibitors of H37Rv strain of 
Mtb.48 Omar and Alafeefy synthesized 2-alkylthio-6-iodo-3-substitued-quinazolin-4-one 
analogues (N) (Figure 16) with three compounds showing more than 95% growth 
inhibition at a minimum inhibitory concentration (MIC) of less than 6.25 μg/mL of Mtb 
strain H37Rv.49 
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A series of novel compounds involving the conjugation of a substituted-quinazolin-
4(3H)-one moiety as a side arm onto a fullerene scaffold were reported by Patel et al. 
This class of quinazolinone-fullerene conjugates were evaluated for in vitro 
antimycobacterial activity against Mtb (H37Ra) with compound O (Figure 16) showing 
effective growth inhibition at MIC 1.562 mg/mL with an inhibition of 98.83%.50 
Additionally, studies by Reddy and co-workers produced compound P exhibiting 97% 
inhibition of Mtb (H37Ra) at 25 μg/mL.51 
More recently, Couturier and colleagues identified quinazolinone Q (Figure 16) by high 
throughput phenotypic screening against Mycobacterium smegmatis as potential anti-TB 
agents. Optimization of Q led to more potent, yet poorly soluble Mtb growth inhibitors, 
three of which advanced to in vivo efficacy studies. These derivatives displayed 



























Figure 16: Quinazolinone analogues that have shown to possess antimycobacterial activity effects. 
 18 
The above examples provide insight into the current medicinal applications of 
quinazolinone-based compounds, including the significance in their recent 
antimycobacterial activity.  
1.4. AIMS AND OBJECTIVES 
1.4.1. OBJECTIVE 
The main objective of this research was to perform SAR studies around the 2-
aminoquinazolin-4(3H)-one core towards optimization of these potential 
antimycobacterial agents with respect to solubility and potency. 
1.4.2. HYPOTHESIS 
The hypothesis was whether it would be possible to identify novel aminoquinazolinone-
based antituberculosis drug leads with favorable solubility, potency and metabolic 
stability. 
1.4.3. SPECIFIC AIMS 
i. Synthesis and in vitro antimycobacterial SAR studies of various 
aminoquinazolinones. 
ii. Profiling with respect to solubility and metabolic stability. 




CHAPTER 2: DESIGN, SYNTHESIS AND PHARMACOLOGICAL EVALUATION OF    
2-AMINOQUINAZOLINONE ANALOGUES 
2.1. INTRODUCTION 
This chapter reports on the design, synthesis and spectroscopic characterization of 
compounds based on the 2-aminoquinazolinone structure (Figure 17). Modifications 
around the core in positions 3 and 6 of the quinazolinone moiety incorporating aryl and 
saturated ring substituents were explored in an attempt to improve solubility. Adapted 
synthetic schemes were employed to achieve the desired target molecules. Some of the 
synthesized compounds were initially tested for in vitro antimycobacterial activity in 
media containing glycerol-alanine-salts with Tween-80 and iron (GAST Fe) as well as 
media that comprises of 7H9 broth with a growth supplement containing bovine 
albumin, dextrose and catalase (7H9 ADC).53 Samples were tested against the virulent 
human Mtb strain, H37Rv,54 whereby the most active derivatives were profiled with 
respect to cytotoxicity and microsomal metabolic stability. Aminoquinazolinone 
intermediates and target compounds were subsequently reevaluated in glycerol-free 
media. The apparent solubility of all target compounds was also measured using kinetic 






Figure 17: General structure of the 2-aminoquinazolinone core scaffold. 
2.1.1. BACKGROUND INFORMATION 
On the basis of the structural similarity shared with previous antimalarial 2-
aminopyridines,55 2-aminoquinazolinones were synthesized for evaluation against the 
human malaria parasite Plasmodium falciparum, but were found to be inactive. 
Subsequent phenotypic whole-cell screening of this series against Mtb identified the 
aminoquinazolinone 5.1 with favourable antimycobacterial potency, but low solubility 













conducted. These studies led to the sulfoxide 5.2, which showed to improve solubility, 










Further profiling of frontrunner compounds 5.1 and 5.2 was ongoing in parallel to the 
research described in this dissertation, whose main focus was to apply the various 
solubility improvement approaches to the hit compound 5.2 whilst also expanding the 
SAR. 
Figure 18: Chemical structure, biological 
activity and solubility data for the hit 
aminoquinazolinone compound 5.1. 
Figure 19: Chemical structure, biological 
activity and solubility data for the sulfoxide-








in vitro  antimycobactrial activity:
MIC99 = 0.625 mM (Day 14, H37Rv in GASTE/Fe)








in vitro  antimycobactrial activity:
MIC99 = 1.25 mM (Day 14, H37Rv in GASTE/Fe)
Kinetic solubility: 80 mM
5.2
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2.2. DESIGN AND RATIONALE OF AMINOQUINAZOLINONE DERIVATIVES 
In order to explore the SAR for this class of compounds, various structural changes 
around the aminoquinazolinone core would need to be implemented. Therefore, a 
variety of analogues were selected for synthesis based on this, resulting in two points of 
diversity, SAR 1 and SAR 2, whilst the aminoquinazolinone core scaffold remained fixed 













Figure 20: Chemistry design for planning the synthesis of aminoquinazolinone derivatives with two 
points of diversity, Ar and R1, around the core incorporating various solubility improvement 
strategies. 
SAR 1 was initially explored with structural modifications occurring at Ar whereas the 
right hand side (RHS) R1 remained fixed. Previous studies revealed that the presence of 
the sulfone moiety in the ortho- and para-positions resulted in inactive (MIC99 > 160μM) 
compounds. This confirmed the meta-position as optimal for activity in respect of Ar 
groups of SAR 1. Substituents were selected not only to create structural diversity and 
expand the SAR, but also to potentially improve solubility properties. Subsequently, a 
number of the aforementioned solubility improvement strategies were considered in 
designing SAR 1 analogues for synthesis, which can be divided into three categories: 














X = OH, NRR, NH2










X = O, S, NMe








Specifically, sulfonyl analogues investigated the reduction of crystal packing through the 
addition of a substituent in the ortho-position to increase the dihedral angle as well as 
interchange of the sulfonylmethyl moiety for a cylcopropyl substituent. The morpholino 
group of compounds incorporates a combination of hydrophilic, polar substituents as 
well as saturated rings to disrupt planarity. Introduction of an ionizable group was 
explored through the addition of a pyridinyl analogue. This was also introduced into the 
amide series whereby the main strategy was to reduce lipophilicity by including polar, 
hydrophilic substituents. 
The choice of Ar substituents was also determined by the commercial availability of the 
appropriate arylboronic acids or esters necessary for the introduction of Ar 
substituents. 
In order to explore SAR 2, various substituents were selected for R1 using the solubility 
improvement approaches, while the Ar and aminoquinazolinone core remained 
unchanged. Previously synthesized analogues of the R1 moiety in which the 
trifluoromethyl group was in the meta- and ortho-positions displayed moderate to poor 
activity, respectively, thereby confirming the necessity of the aromatic substituent to be 
in the para-position for SAR 2 derivatives. 
The main focus for selection of substituents for SAR 2 analogues was the removal of 
aromaticity as a strategy to improve solubility (Figure 20). Variations in chain length as 
well as the incorporation of hydrophilic substituents were additionally explored. 





2.3. SYNTHESIS AND SPECTROSCOPIC CHARACTERIZATION OF 2-
AMINOQUINAZOLINONES 
2.3.1. SYNTHESIS OF SAR 1 TARGET COMPOUNDS 
Literature on the synthesis of 2,3-disubstituted quinazolinone compounds, particularly 
for the 2-amino derivatives, is rare as much of the literature is dominated by 
unsubstituted quinazolinone-based compounds.56,57 However, Leivers and coworkers 
recently described a synthetic procedure for the formation of 2-aminoquinazolinones as 

















Scheme 1: General synthetic protocol towards target compounds 5.1 – 5.11. Reagents and 
conditions: (i) Dioxane, Et3N, reflux (110 °C), 4 h; (ii) POCl3, PCl5, N2, 110 °C, 6-12 h; (iii) DMF,                
4-methoxybenzylamine, DIPEA, 80 °C, 4 h; (iv) TFA, reflux, 48 h or MW (110 °C) 20 min, (v) 
Dioxane/water, ArB(OH)2, PdCl2(PPh3)2, K2CO3, 80 °C, 1-5 h.  
The SAR 1 target compounds were therefore synthesized using the synthetic procedure 
outlined in Scheme 1, adapted from work reported by Leivers and coworkers. Briefly, 
the synthesis involved commercially available 2-amino-5-iodobenzoic acid and 4-
(trifluoromethyl)phenyl isothiocyanate, which undergo a cyclization reaction to afford 
intermediate 1.  
Chlorination of the thioxo intermediate was achieved using phosphorous oxychloride 
(POCl3) in the presence of phosphorous pentachloride (PCl5) to give the 2-chloro 
intermediate 2. The amino group was then installed using 4-methoxybenzylamine in a 


















































trifluoro acetic acid (TFA) to afford the 2-aminoquinazolinone 4. The desired Ar 
substituent was then incorporated via a Suzuki-Miyaura cross-coupling reaction 
between the penultimate iodo compound 4 and the appropriate boronic acid or ester to 
form target compounds 5.1 – 5.11 in low to high yields (Table 1). 






Ar Variables Percentage Yield (%) 
5.1 
(JA025) 
   46 
5.2 
(JA010) 
    40 
5.3 






Y = CH, X = O 87 
5.5 
(JA019) 
Y = CH, X = S 83 
5.6 
(JA020) 
Y = CH, X = NMe 32 
5.7 
(JA021) 
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2.3.2. MECHANISTIC DETAILS AND SPECTROSCOPIC ANALYSES OF SAR 1 
INTERMEDIATES AND TARGET COMPOUNDS  
The proposed mechanism for step (i) is initiated by a nucleophilic attack of the amino 
nitrogen of 2-amino-5-iodobenzoic acid on the electron deficient isothiocyanate carbon 
(Figure 21). This is followed by a proton transfer step between the two nitrogens on the 
thiourea intermediate to allow for intramolecular cyclization to occur. This is achieved 
via an attack at the acyl centre, which is hypothesized to be activated through 
interaction of the carbonyl oxygen with triethylammonium ion, to afford the 
















Figure 21: Proposed reaction mechanism for the formation of quinazolinone intermediate 1.  
The structure of compound 1 was confirmed by 1D 1H NMR (Figure 22), consisting of a 
broad, highly deshielded, singlet proton signal resonating at δ 13.18, which is 
characteristic of the quinazolinone proton (H-6). The structure is further confirmed by 
the conserved coupling pattern observed in the aromatic region including a diagnostic 
long-range coupling (4J = 1.92 Hz) between H-1 (δ 8.20) and H-2 (δ 8.10) as well as the 
presence of two, symmetrical doublets corresponding to the disubstituted 4-




































































Figure 22: Assigned 1H NMR spectrum confirming the successful synthesis of intermediate 1. 
 The chlorination reaction (ii) is proposed to proceed via an attack of the 2-thioxo center 
on the phosphorous of POCl3/PCl5 with the loss of a chloride ion. The chloride then 
attacks the electrophilic thiocarbonyl carbon resulting in elimination of phosphenothioic 
chloride and the release of hydrochloric acid (HCl) to afford the 2-chloro intermediate 2.  
POCl3 is used in conjunction with PCl5, as previous attempts with using only POCl3 as the 

























































































































1H NMR confirmed successful chlorination due to the absence of the key diagnostic 
quinazolinone amino proton signal in intermediate 2 that was previously observed in 
intermediate 1, whilst the quinazolinone core proton signals (H1, H2, H3) remain intact 















Figure 24: 1H NMR spectrum of chlorinated intermediate 2. 
With a good leaving group in the 2-position, the 4-methoxybenzylamino group is 
introduced via a nucleophilic aromatic substitution reaction (SNAr) of the chloro group, 
which is assisted by the push of electrons through the conjugated ring system of the 
quinazolinone core (Figure 25). 
Figure 25: Proposed mechanism for the SNAR reaction in the formation of intermediate 3. 
The appearance of new proton signals corresponding to the aminobenzyl in the 1H NMR 
spectrum (Figure 26) confirmed that successful nucleophilic substitution had occurred. 
Characteristic signals include the broad NH triplet at δ 6.68, the benzylic methylene 

























































Figure 26: 1H NMR spectrum for the methoxbenzylamine intermediate 3. 
The key 2-aminoquinazolinone intermediate 4 was generated via a deprotection 
reaction catalyzed by TFA and assisted by the push of electrons through the benzyl ring 
to afford the desired free amino group, as mechanistically shown in Figure 27.  
Figure 27: Proposed mechanism for the deprotection reaction using TFA. 
1H NMR confirmed successful deprotection with the presence of a broad singlet at δ 6.60 










































































Figure 28: 1H NMR spectrum for deprotected intermediate 4. 
The final step in synthetic Scheme 1 introduces the structural diversity of Ar 
substituents via a Suzuki-Miyaura cross-coupling reaction, which is a palladium-
catalyzed reaction between an aryl halide and an aryl boronic acid or ester to form 
biaryl systems. The mechanism was first published by Suzuki in 1985 and proceeds via a 
catalytic cycle incorporating three major steps; oxidative addition, transmetallation and 
reductive elimination.58 
Structural assignments for final target compounds (5.1 – 5.11) were assisted by 2D 
heteronuclear single quantum correlation (HSQC) and correlation spectroscopy (COSY) 
NMR experiments. For characterization purposes compound 5.1 is used as an 
illustrative example of the coupling pattern observed for the target compounds, with the 
addition of signals relating to the Ar substituents (Figure 29). For example, a highly 
deshielded triplet (δ 8.20) is observed with a small coupling constant (4J ~ 1.81) owing 
to long range coupling from H-7 to H-8 and to H-10. This is reflected in the splitting 
pattern for these two protons, which are additionally coupled to H-9 (3J = 7.81) as well 
as to each other, therefore a doublet of doublet of doublets (ddd) or doublet of triplets is 
observed for these two protons, with a corresponding triplet correlating to H-9 at δ 7.75. 
This coupling pattern is observed for most of the meta-substituted aromatic 









































Figure 29: 1H NMR spectrum of final target compounds, using 5.1 as an illustrative example. 
 
2.3.3. SYNTHESIS OF SAR 2 TARGET COMPOUNDS 
In order to create structural diversity for SAR 2 using synthetic Scheme 1, different R1 
substituents would need to be introduced using various arylisothiocyanates. However, 
these have limited commercial availability and therefore, alternative synthetic 
procedures were explored. 
Work reported by Lecoutey and coworkers describing a one-pot synthesis of 2-
aminoquinazolinones using methyl anthranilate as the starting material and 
incorporating structural diversity in the 3-position using commercially available 
primary aromatic amines (anilines) was considered.59 However, previous attempts by 
our research group using methyl 2-amino-5-bromobenzoate as a starting material failed, 


























Scheme 2: General synthetic protocol towards target compounds for SAR 2. Reagents and 
conditions: (i) Acetonitrile, rt (24.4°C), 10 min; (ii) DCM, EDCI, R1NH2, rt (24°C), 18 h; (iii) TFA, MW, 
110°C, 20 min; (iv) DMF, EDCI, R1NH2, rt (5h)  100°C (18–22h); (v) Dioxane, B2pin2, PdCl2(dppf), 
KOAc, 80 °C, 2 h; (vi) Dioxane/water, PdCl2(PPh3)2, K2CO3, 80 °C, 5 h.   
 
Briefly, the modified synthetic protocol involves an initial reaction between methyl 2-
amino-5-bromobenzoate and ethoxycarbonyl isothiocyanate to form the isolated 
thioureido intermediate (6.1). This intermediate then undergoes cyclization and a 
simultaneous amide coupling reaction with the appropriate amine using N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDCI) as a coupling agent 
in dichloromethane (DCM) at 24°C to yield carbamate intermediates 7.5 and 7.6. The 
methyl ester was then cleaved in an acid-catalyzed reaction to afford the 2-





Table 2: Isolated percentage yields for SAR 2 intermediates and target compounds.  
     
























69 % 83 % 11 % COOH 
 
It was found that some intermediates underwent coupling to the amine but subsequent 
cyclization was not observed. Therefore, upon substitution of DCM for N,N-dimethyl 
formamide (DMF), and allowing the reaction to proceed at 24 – 26°C for 5 hours to form 
the uncyclised intermediate, the temperature was raised to 100°C under pressure and 
stirred for 18 – 22 hours. This allowed for intramolecular cyclization and deprotection 
of the ester to take place resulting in the aminoquinazolinone intermediates 8.1 – 8.4 in 
one step (iv).  
Finally, the Ar substituent of the parent compound was incorporated using 3-
methylsulfinylphenylboronic acid via the Suzuki-Miyaura cross-coupling reaction to 
obtain final SAR 2 target compounds 9.1 – 9.5. The yields of intermediates and target 
compounds are summarized in Table 2. 
Previous attempts at synthesizing SAR 1 compounds 9.6 and 11 using Scheme 1 were 
unsuccessful. For this reason, Scheme 2 was adopted in the synthesis of these 


























The carboxylic acid moiety was installed for target compound 9.6 by reacting 8.6 with 
3-carboxyphenylboronic acid at step vi. The synthesis of 11 was slightly different in that 
intermediate 8.6 was transformed into a boronic acid pinacol ester (10) using 
bis(pinacalato)diboron, to which the Ar substituent was installed by reacting 10 with 2-
bromo-1-methyl-4-(methylsulfonyl)benzene as the aryl halide, under Suzuki-Miyaura 
cross-coupling conditions to afford target compound 11.    
2.3.4. MECHANISTIC DETAILS AND SPECTROSCOPIC ANALYSES OF SAR 2 
INTERMEDIATES AND TARGET COMPOUNDS  
The key difference between SAR 1 and SAR 2 synthetic protocols occurs at step ii in 
Scheme 2. The proposed mechanism for step ii proceeds via an attack on the 
electrophilic carbon of EDCI by the nucleophilic quinazolinone sulfur to form an 
activated thiourea complex. This enables coupling of the appropriate amine at the 
methylene centre to allow for intramolecular cyclization to occur at the acyl centre, to 






















Figure 30: Proposed mechanism for step ii, amide coupling and intramolecular cyclization reaction. 
Deprotection of the carbamate moiety in DMF at high temperatures in step iv is 
postulated to be facilitated by the thiourea byproduct formed previously to furnish the 




























































in Figure 31. The carbamate ester is lost as an ethyl carbocation and the reaction is 
driven by release of carbon dioxide gas. The anion intermediate formed is resonance 











The structures of the SAR 2 target compounds and their relevant intermediates were 
confirmed by 1D and 2D NMR experiments. Using intermediate 8.1 as an illustrative 
example (Figure 32), it is evident that the 1H NMR spectra are slightly more complex, 
particularly in the aliphatic region due to the saturated ring system of the R1 
substituents. The splitting pattern observed is due to cis-trans isomerism, which occurs 
in 1,4-disubstituted cylcohexanes due to the relative conformational relationship 







Figure 31: Proposed mechanism for the hydrolysis of the carbamate moiety in the formation of 


























































































Cis-isomers have substituents pointing in the same direction with both conformational 
diastereomers having an axial-equatorial relationship at equilibrium (Figure 33.i). 
Conversely, trans-isomers have both substituents either in the axial or in the equatorial 
positions and pointing in opposite directions (Figure 33.ii). The conformations with 
substituents in the equatorial position are most energetically favoured and therefore, 











Figure 33: Cis-trans isomerism of 1,4-disubstituted cyclohexanes upon chair interconversion at 
































The starting materials used to introduce these substituents contained only one isomer 
and therefore various analytical experiments were performed to confirm the 
conformation of these 1,4-disubstituted compounds. Liquid chromatography-mass 
spectroscopy (LCMS) showed the presence of only one isomer as one peak was observed 
in the chromatogram and this was substantiated by the 1H NMR experiment with signals 
correlating to one compound present. Assignments of axial and equatorial protons on 
the non-substituted carbons were established from the splitting pattern of these signals 
in the 1H NMR spectra, assisted by HSQC, COSY and (nuclear Overhauser effect 
spectroscopy) NOESY experiments.  
Figure 34: Chair conformation of the favoured trans isomer with substituents in equatorial position 
showing coupling interactions of the axial protons (red) and equatorial protons (blue). 
 
Using the favoured trans-isomer with substituents in the equatorial positions (Figure 
34), axial protons (H-6ax) exhibit large coupling values to the neighbouring axial protons 
(H-7ax and H-5) as well as to its geminal proton (H-6eq), resulting in a quartet with a J-
value of 12-13 Hz, as illustrated in Figure 34 in red. Additionally, these axial protons can 
sometimes experience a small coupling (~3-4 Hz) to the vicinal, equatorial proton (H-
7eq), resulting in the quartet to split into a quartet of doublets (δ 2.59) if the resolution of 
the spectrum is good enough. The equatorial protons (H-6eq) therefore exhibit large 
coupling to its geminal axial protons (H-6ax), forming a doublet (δ 1.66), which can 
sometimes split into a doublet of doublets if coupling to the vicinal axial proton (H-7ax) 




























Figure 35: Extract from NOESY experiment of 8.1 to establish relative through-space interactions of 
the substituted protons to determine their cis or trans relationship. 
  
In order to establish the relative relationships between substituents, NOESY 
experiments were used as this technique determines through-space correlations 
between protons. Looking at the signals for the protons on the substituted carbons (H-5 
and H-8) in Figure 35, it can be observed that they exhibit through-space correlations 
with different pairs of protons, suggesting that they point in opposite directions ie. 
trans-isomer. Using the favoured trans-isomer with substituents in the equatorial 
positions, through-space interactions of H-5 with H-6eq and H-7ax are observed, whereas 
H-8 experiences correlations with H-6ax and H-7eq. This confirms that the trans-isomer 









2.4. PHARMACOLOGICAL EVALUATION OF TARGET COMPOUNDS 
The biological evaluation of synthesized target compounds were determined using 
various assessments as outlined in the screening cascade depicted in Figure 36. Once 
synthesized, all compounds were submitted for antimycobacterial evaluation as well as 
solubility studies using turbidimetric and kinetic solubility assays. Potent analogues that 
inhibit Mtb growth with 99% inhibition at a minimum concentration (MIC99) of 10μM or 
less were further evaluated for cytotoxicity against the mammalian Chinese Hamster 
Ovarian (CHO) cell line. If found to have an acceptable cytotoxicity profile, they were 
assessed for microsomal metabolic stability whereby analogues with more than 75% of 
its parent compound present after 30 minutes are deemed metabolically stable. 
Compounds that fulfill these criteria would be further screened for in vivo 
pharmacokinetics to establish properties such as bioavailability (F), exposure (AUC) and 
clearance (Cl) for the eventual efficacy studies in a mouse model. However, these assays 




























Figure 36: Screening cascade outlining the criteria for progression of work-flow from synthesis to in 














2.4.1. IN VITRO ANTIMYCOBACTERIAL ACTIVITY AND CYTOTOXICITY 
Synthesized SAR 1 target compounds were submitted for antimycobacterial activity 
evaluation against the H37Rv strain of Mtb. Studies were performed in both GAST Fe 
and 7H9 ADC media and reported as MIC99 values at day 14 (Table 3). 








In vitro antimycobacterial 
activity MIC99 (μM) Cytotoxicity 
















2.35 1.28 0.021 ± 0.0048 
11 
(JA038) 




Y = CH, X = O 4.93 1.73 8.77 ± 1.08 
5.5 
(JA019) 
Y = CH, X = S 0.656 0.351 >50 
5.6 
(JA020) 
Y = CH, X = NMe 1.57 1.54 >50 
5.7 
(JA021) 
Y = N, X = O 83 69.5 ND 
5.8 
(JA017)  
Y = CH, 
R = R' = H 
0.92 < 0.244 >236 
5.9 
(JA022) 
Y = CH, 
R = H, R' = Me 
0.78 < 0.244 96.3 ± 1.05 
5.10 
(JA023) 
Y = N, 
R = H, R' = Me 
9.22 4.13 ND 
5.11 
(JA016) 
Y = CH, 
R = R’ = Me 





112 8.1 >50 
Control   
Rifampicin Emetine 
0.00213 0.00218 0.018 ± 0.004 
























The in vitro antimycobacterial activity results depicted in Table 3 generally indicate 
comparable MIC99 values across all compounds (<10 μM), exhibiting promising 
inhibitory effects on the H37Rv strain of Mtb, with the exception of 5.7 and 9.6. Upon 
observation of trends within different groups of compounds, the addition of the 
cyclopropyl moiety (5.3) in the sulfone series, as well as the introduction of a methyl 
substituent in the ortho-position of the biaryl moiety (11), resulted in compounds with 
comparable activity to the sulfone 5.1 and sulfoxide 5.2 parent compounds, in the 7H9 
media in particular.  
Comparing the activity of heterocyclic amides 5.4 – 5.7, excellent inhibitory effects were 
shown by thiomorpholine 5.5, followed by the methylpiperazine 5.6 in both media. The 
pyridinyl derivative (5.7) was found to be the least active of this series. 
The amide analogues followed the trend of NMe2 (5.11) > NH2 (5.8) > NHMe (5.9) in 
GAST Fe media, with the secondary amine (5.9) displaying the most promising activity 
of the amide series. However, a slight loss of activity was observed for 5.10 upon 
replacement of the phenyl ring (Y = C) with a pyridinyl ring (Y = N) in both media. 
Moving from the amides to the carboxylic acid derivative (9.6) resulted in relatively 
poor activity, especially in the GAST Fe media.  
According to the screening cascade in Figure 36, compounds that exhibited promising 
antimycobacterial activity (MIC99 ≤ 10 μM) were selected for cytotoxicity evaluation 
against a mammalian cell-line, CHO, using Emetine as a reference control. With the 
exception of compounds 5.3, 5.4 and 5.11, all other target compounds displayed low 
cytotoxicity (Table 3). 
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2.4.2. MICROSOMAL METABOLIC STABILITY 
The in vitro microsomal metabolic stability of a selected sample of SAR 1 compounds 
with in vitro antimycobacterial activity of MIC99 less than 10 μM, was determined in 
human liver microsomes (HLM), rat liver microsomes (RLM) and mouse liver 
microsomes (MLM). Samples were incubated for 30 minutes and analysed by high 
performance liquid chromatography-mass spectrometry (HPLC-MS/MS) to determine 
the percentage remaining. 
Table 4: Microsomal metabolic stability results of selected SAR 1 compounds, reported as a 





ND = Not Determined 
Compound Ar Variable 
Metabolic Stability  
(% Remaining) 
HLM RLM MLM 
5.1 
(JA025) 
  97.0 100 92.0 
5.2 
(JA010) 





85.0 97.6 97.1 
11 
(JA038) 
  64.8 85.8 89.9 
5.4 
(JA018)  
Y = CH, X = O 71.0 76.9 77.6 
5.5 
(JA019) 
Y = CH, X = S 83.0 22.9 22.0 
5.6 
(JA020) 





Y = CH, 
R = R' = H 
88.0 ND ND 
5.9 
(JA022) 
Y = CH, 
R = H, R' = Me 
97.6 100 100 
5.11 
(JA016) 
Y = CH, 
R = R’ = Me 
85.0 86.3 88.5 
9.6 
(JA039)   
























A value of more than 75% concentration of tested compound remaining is within 
acceptable limits, based on the screening cascade in Figure 36. Therefore, results 
obtained in Table 4 suggest good metabolic stability of SAR 1 compounds in liver 
microsomes across the three species.  
The morpholine derivatives 5.4 and 5.6 were moderately stable across all species. 
However, thiomorpholine 5.5 shows high metabolically stability in HLM but displays 
substantial instability in RLM and MLM. This difference may be due to differences in CYP 
enzymes across species that are responsible for specific reactions. Metabolite 
identification studies would need to be performed to ascertain precise metabolic 
reactions, and where they are occurring on the molecule.  
Suffice to conclude that several compounds could be evaluated in vivo as they would be 
expected to have good exposure in mice based on the metabolic stability data in MLM.  
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2.4.3. EVALUATION OF GLYCEROL DEPENDENCY 
2.4.3.1. Glycerol-Free in vitro Assays 
Despite exhibiting favourable in vitro potency and PK properties, compound 5.2 failed to 
show in vivo efficacy in the acute mouse TB model. As a result, further studies into the in 
vitro assays were explored in an effort to understand the lack of in vivo efficacy. One 
possible hypothesis for the lack of in vivo efficacy might be due to differences in carbon 
sources for Mtb under in vitro conditions and in vivo in mice. For this reason, 
collaborators at Colorado State University (CSU) subsequently retested compound 5.2 in 
different carbon source media, which contained 7H12 broth media, casitone, palmitic 
acid, bovine serum albumin (BSA), catalase and Tween-80, as well as two different Mtb 
strains were explored, Erdman and H37Rv (Table 5).  
Table 5: In vitro MIC results for compound 5.2 from CSU using glycerol-containing and 








MIC in mg/L for: 
5.2 Rifampin Isoniazid 
Erdman 7H9 + glycerol + ADC 1 0.03 0.016 
H37Rv 7H9 + glycerol + ADC 0.5 0.016 0.016 
Erdman 
7H12 + casitone + palmitic acid + BSA + 
catalase + Tween-80 
>16 <0.008 0.016 
H37Rv 
7H12 + casitone + palmitic acid + BSA + 
catalase + Tween-80 
>16 <0.008 0.016 
MIC assays repeated in 7H9, glycerol and ADC media revealed similar activity to those 
reported from UCT, with 5.2 shown to be active only in glycerol-containing media. 
To further substantiate these findings, collaborators at the National Institute of Allergy 









“active” SAR 1 aminoquinazolinones (Figure 37) in media containing glucose as the 
carbon source in 7H9 broth with BSA or casitone as the amino acid source and tyloxapol 
as the surfactant component. Consistent with data obtained at CSU, these were also 






Figure 37: General structure of SAR 1 analogues with varying Ar substituents. 
 
Whilst in vivo studies were being investigated, some SAR 2 compounds were 
simultaneously synthesized and tested for in vitro antimycobacterial activity utilizing 
new media (GAST Fe and 7H9 Glu ADC) containing glucose as the carbon source. All 
intermediates and target compounds of the SAR 2 series (Figure 38) exhibited poor 
activity (MIC99 > 50 μM), possibly suggesting dependency on glycerol in the media for 
inhibition of Mtb growth. 
Figure 38: General structures of intermediates 7 – 8 and target compounds 9.1 – 9.5 that were 
evaluated for in vitro antimycobacterial activity in glycerol-free media. 
 
There are many factors that contribute to the growth of Mtb in vitro and in vivo, one of 
which is the presence of a suitable carbon source as carbon metabolism plays a major 
role in the ability of Mtb to replicate and persist in the host. Therefore, it is able to 
metabolically adapt to the host’s environments depending on the nutrients available, as 
Mtb is capable of oxidizing multiple carbon sources. This ability is key to the 
pathogenicity of Mtb.60 
 
Despite Mtb being able to grow on a variety of carbon sources in vitro, glycerol has long 
been the preferred source of energy and carbon for Mtb under in vitro conditions and is 


























The discrepancy between the in vitro activity and in vivo efficacy of the 
aminoquinazolinone series was explained by a major difference in carbon metabolism 
between bacteria replicating in a standard broth medium as compared to an infected 
host.61 The lack of in vivo efficacy of aminoquinazolinone compound 5.2 suggests that 
glycerol is not a carbon source either readily available, or primarily used by Mtb in 
mouse lungs and that the aminoquinazolinone series exert their inhibitory effect in vitro 
by dysregulating the glycerol dissimilation pathway.62 This data is consistent with that 
reported by researchers at the Novartis Institute of Tropical Diseases (NITD) in 2010.61 
 
The presence of glycerol in the media leads to the build up of glycerol-3-phosphate 
(G3P) and dihydroxyacetone phosphate (DHAP) by these compounds which induces 
toxic consequences to Mtb as accumulation of sugar phosphates is known to be highly 
toxic for most bacteria.61 Previous studies showed that compounds with glycerol-
specific activity promote the accumulation of G3P resulting in a rapid depletion of 
adenosine triphosphate (ATP) utilized for phosphorylation of glycerol essentially 
leading to self-poisoning of Mtb.61,63 
These results highlight the importance of validating the relevance of in vitro assay 
conditions to reproduce the environment encountered by Mtb in the infected host.61,62 
2.5. CONCLUSIONS 
In summary, 18 aminoquinazolinone target compounds were successfully synthesized 
and characterized. Of these, 13 SAR 1 compounds were evaluated for antimycobacterial 
activity in glycerol-containing media with 11 of them showing promising activity. These 
were subsequently evaluated for cytotoxicity and microsomal metabolic stability. 
Retesting of SAR 1 and SAR 2 intermediates and target compounds in glycerol-free 
media revealed inactivity of all target compounds, suggesting glycerol-dependency of 





CHAPTER 3: SYNTHESIS AND BIOLOGICAL EVALUATION OF ACTIVE 
AMINOQUINAZOLINONE INTERMEDIATE ANALOGUES 
3.1. BACKGROUND INFORMATION 
Approximately 90 aminoqinazolinone analogues were collectively synthesized by other 
members of our team. Of these, 35 analogues showed moderate to excellent in vitro 
antimycobacterial activity in various glycerol-containing media. All intermediates and 
target compounds were subsequently retested in glycerol-free in vitro assays with all, 
but one intermediate 7.7 (Table 6), displaying complete loss of activity (MIC99 >50).   
Table 6: In vitro antimycobacterial activity results for intermediate 7.7 against Mtb (H37Rv) 






In vitro antimycobacterial activity, MIC99 (μM) 





Day 7/Day 14 Day 7/Day 14 Day 7/Day 14 Day 7/Day 14 
1.2 / 1.56 1.2 / 1.56 6.25 / 3.13 2.3 / 4.7 
 
This chapter therefore describes the synthesis and characterization of derivatives of 7.7, 
exploring variations in regioisomers and hydrogen-bonding properties towards 
establishing whether or not antimycobacterial activity can be retained in glycerol-free 
media.  
3.2. TARGET AMINOQUINAZOLINONE INTERMEDIATE ANALOGUES 
Structural modifications were envisaged on 7.7 focusing on three points of diversity 
(SAR 3, SAR 4 and SAR 5) for the synthesis of new analogues (Figure 39). 
Analogues for SAR 3 involved structural modifications at R2 whilst the carbamate and 









it was observed that the phenol group was essential for activity. Therefore regioisomers 
with the hydroxyl moiety in the ortho- and meta-positions around the ring were 
targeted. Additionally, alternative HBD substituents were employed (eg. NH2). Since 
compound 7.7 possessed poor solubility (kinetic solubility at pH 7.4 <5) the solubility 
improvement strategy of removing aromaticity was again investigated. In SAR 4, bromo 










Figure 39: Chemistry design for planning the synthesis of quinazolinone analogues derived from 7.7 
with three points of diversity around the core. 
SAR 5 explored variations of the carbamate moiety. Upon reviewing the literature on 
quinazolinones, work reported by Khadka and coworkers describe the synthesis of 2-
arylquinazolinones as potential inhibitors of topoisomerases for the treatment of 
cancer.64 These structures were therefore incorporated into SAR 5 to determine 
whether replacement of R2 substituents into the R3 position would have any 
antimycobacterial effects. Feasibility of the synthesis of such derivatives was also 
considered for all SAR 5 analogues.  
3.3. SYNTHESIS AND SPECTROSCOPIC CHARACTERIZATION OF 
AMINOQUINAZOLINONE INTERMEDIATES 
3.3.1. SAR 3 TARGET COMPOUNDS 
The synthesis of SAR 3 and SAR 4 derivatives were adapted from the protocol outlined 
in synthetic Scheme 3. Since the carbamate moiety was to remain fixed, only the first 
two steps of the synthesis were required.  
Essentially, the synthesis involved the formation of a thioureido intermediate 6.1, as 














this intermediate and the appropriate amine were dissolved in either DCM or DMF, 
depending on their solubilizing ability, and were subsequently treated with the coupling 
agent, EDCI, to produce the desired cyclic target compounds 7.1 – 7.4 and 7.7 in low to 
high yields (Table 7).  
 
Scheme 3: General synthetic protocol towards SAR 3 compounds 7.1 – 7.4 and 7.7. Reagents and 
conditions: (i) Acetonitrile, 24°C, 30 min; (ii) DCM/DMF, R2NH2, EDCI, 21 – 25°C , 18 h. 
 










































The NMR spectra of SAR 3 analogues have key diagnostic signals occurring in the 
aromatic region due to changes in the R2 position, with the appearance of aliphatic 
signals for 7.3 as a result of the introduction of a saturated ring.  The core quinazolinone 
and carbamate signals remain constant as shown by new hit compound 7.7 (Figure 40). 
Analogues with para-substituted R1 substituents (7.4 and 7.7) exhibited an AB splitting 





















Figure 40: 1H NMR spectrum of new hit compound 7.7. 
 
Displacement of the hydroxyl group around the ring for analogues 7.1 (ortho) and 7.2 
(meta) resulted in a change in the characteristic aromatic signals due to removal of the 
axis of symmetry. Using 7.2 as an example (Figure 41), four proton signals appear in the 
δ 6.7 – 7.3 region, with long-range coupling (4J) being observed between H-7, H-9 and H-





































Figure 41: 1H NMR spectrum of saturated phenol derivative 7.2. 
 
Removal of aromaticity for 7.3 resulted in the appearance of axial-equatorial coupling 
pattern for H-8 and H-9 in the aliphatic region due to cis-trans isomerism, as observed 
for SAR 2 compounds. Interestingly, a triplet of doublets is observed for H-10 at δ 3.44 
due to large coupling to neighboring H-9ax protons (3J = 10.99) to form a triplet with 
additional coupling to the hydroxyl proton, which results in the splitting of the triplet 
into doublets to form a td splitting pattern (Figure 42). Relative stereochemistry was 
established by the amine starting material used with confirmation of axial/equatorial 
proton signals determined from 2D NMR, specifically NOE spectroscopy, as described 































Figure 42: 1H NMR spectrum of saturated SAR 3 analogue 7.3. 
3.3.2. SAR 4 TARGET COMPOUNDS 
The synthesis of SAR 4 analogues differs from that previously described for SAR 2 and 
SAR 3 as it utilizes methyl 2-amino-4-bromobenzoate and methyl 2-amino-6-
bromobenzoate as starting materials. Compounds 7.8 and 7.9 were formed by reacting 
the resulting thioureido intermediates 6.2 and 6.3 with 4-aminophenol in a cyclization 
and amide coupling reaction with moderate yields (Scheme 4). The synthesis of SAR 3 
and SAR 4 compounds follow closely to the first two steps of SAR 2, and the mechanism 










Scheme 4: General synthetic protocol towards SAR 4 compounds 7.8 and 7.9. Reagents and 















































6.2:  4-Br , 73%
6.3:  6-Br , 35%
7.8:  4-Br , 41%




Key structural changes to the quinazolinone core brought about by SAR 4 analogues can 
be illustrated using 1H NMR spectra of intermediates 6.2 and 6.3. Using 6.1 as a 
reference in Figure 43, the order of chemical shift signals in the aromatic region remain 
relatively the same with varying splitting patterns, depending on its neighboring 
protons. 
 
Figure 43: Stacked 1H NMR spectra of SAR 4 intermediates, 6.2 (2) and 6.3 (3), indicating key 
structural changes to the quinazolinone core in comparison to 6.1 (1).  
 
3.3.3. SAR 5 TARGET COMPOUNDS 
The synthesis of compounds 12.1 and 12.2 utilizes compound 7.7 (Scheme 5) and 
further diversifies the carbamate moiety by initially cleaving the methyl ester off via an 
acid catalyzed reaction with TFA to form the 2-aminoquinazolinone intermediate 8.7. 
The intermediate was then heated in acetic anhydride to 100°C to acetylate the amine in 
the 2-position. It was found that upon heating the solution to reflux, acetylation also 
occurred at the phenol moiety (12.1) and the diacetylated byproduct 12.2 was 












































Scheme 5: General synthetic protocol towards SAR 5 compounds 12.1 and 12.2. Reagents and 
conditions: (i) TFA, MW 110 °C, 60 min; (ii) Ac2O (1.1 Eq.), 100 °C; 2 h (iii) Ac2O (2.0 Eq.), 140 °C, 20 h. 
 
Replacement of the carbamate moiety resulted in changes in the aliphatic region. Initial 
addition of a single acetyl group to the more susceptible amine was confirmed by the 
appearance of a singlet at δ 1.87 (Figure 44-2), whilst the OH signal (δ 9.76) remained in 
place. Two methyl singlets at δ 2.20 and δ 2.31, with the disappearance of the hydroxyl 
proton signal (Figure 44-3) provided evidence for the diacetylated product. The phenol 
proton signal patterns differ in that when the hydroxyl group is in place (Figure 44-1 
and 44-2), H-6’s and H-7’s are chemically equivalent but magnetically non-equivalent, 
resulting in distorted doublet of doublets.  The addition of the acetyl group results in 























































The synthesis of 2-arylquinazolinone analogues 12.3 and 12.4 outlined in Scheme 6 
involves a thermal cyclodehydration/dehydrogenation reaction between bromo-
substituted anthranilamides and different benzaldehydes in the presence of N,N-









Scheme 6: General synthetic protocol towards SAR 5 compounds 12.3 and 12.4. Reagents and 






















































Figure 44: Stacked 1H NMR spectra of SAR 5 compounds, 12.1 (2) and 12.2 (3) indicating key 














12.3:  R = H , 68%
12.4:  R = OH ,  58%
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The mechanism for the cyclodehydration/dehydrogenation reactions is initiated by the 
protonation of the aldehyde by NaHSO4 to activate the carbonyl moiety and make it 
more susceptible to attack by the neutral amine nucleophile. Following nucleophilic 
addition to the electrophilic carbonyl carbon, proton transfer allows for the formation of 
a better leaving group, enabling attack of the amide nitrogen to the electrophilic acyl 
centre in a dehydration step. Dehydrogenation by NaSO4– and water provides the 










Figure 45: Proposed dehydration/dehydrogenation reaction mechanism for the formation of 
arylquinazolinone derivatives 12.3 and 12.4. 
The 1H NMR spectra of the 2-arylquinazolinone derivatives (Figure 46) varied as 
characteristic signals for the phenol moiety shifted. The aromatic H-5 signal was greatly 
deshielded as evidenced by the shift from ~ δ 7.10 in 7.7 to δ 8.80 in 12.4, owing to the 































































3.4. PHARMACOLOGICAL EVALUATION OF SYNTHESIZED COMPOUNDS 
3.4.1. IN VITRO ANTIMYCOBACTERIAL ACTIVITY 
The synthesized derivatives were evaluated for their in vitro antimycobacterial activity 
against the H37Rv strain of Mtb using modified assay protocols, without glycerol as the 
carbon source, in order to establish SAR. Results reported in Table 8 as MIC90 and MIC99 
at day 14. 























In vitro antimycobacterial activity (Day 14) 









































 > 125 > 125 > 125 > 125 
7.9 
(JA069) 





































> 125 > 125 > 125 > 125 
12.4 
(JA073) 
H  > 125 > 125 > 125 > 125 
Control  Rifampicin  0.011 0.00561 0.118 0.0537 
  Glycerol dependent control  1.19 > 125 
 
Evidently, having the hydroxyl group in the para-position is vital for activity since 
derivatives with the substituent in the ortho (7.1) and meta (7.2) positions displayed 
complete loss of activity. Replacement of the hydroxyl with an amino group (7.4) and 
removal of aromaticity (7.3) were both detrimental to activity.  
 
On the other hand, having the bromo substituent in the 5-position of the quinazolinone 
core is necessary for activity as the other regioisomers (7.8 and 7.9) were inactive. 
When the carbamate moiety was replaced by an amide group, the resulting compound 
(12.1) was inactive. However, the diacetylated compound (12.2) displayed some 
modest potency against Mtb in the GAST Fe media (MIC90 = 44.2 μM and MIC99 = 69.6 
μM). Both 2-arylquinazolinone derivatives (12.3 and 12.4) were inactive (MIC values > 
125 μM).  
 
Evidently, the initial intermediate (7.7) that displayed activity even in glycerol-free 
media incorporated substituents, which were necessary for Mtb growth inhibition in 
ideal positions around the quinazolinone core. This is hypothesized to be due to the 
formation of a reactive metabolite on the phenol moiety attached to a nitrogen as is 
known for amodiaquine.65,66  
 
Amodiaquine undergoes metabolic oxidation by cytochrome P450 enzymes in vivo to 
form toxic amodiaquine quinoneimine (AQQI) metabolites. The antioxidant glutathione 









system. However, glutathione levels in the cell get depleted at high doses resulting in 
reactive toxic metabolites of AQQI analogues reacting with thiol-containing human 
proteins, which form drug-protein adducts that are fatal to the liver cells (Figure 47). 













Figure 47: Mechanism by which amodiaquine undergoes metabolism to form a reactive metabolite, 
which under high doses, can result in toxicity effects. 
It is therefore hypothesized that this phenomenon could be occurring with 7.7, resulting 
in a toxic fragment, which could be responsible for the observed in vitro 
antimycobacterial activity in glycerol-free media. Since the nitrogen does not have a 
proton attached, the mechanism of such metabolism is proposed to proceed via an initial 
enzyme-mediated nucleophilic attack at the acyl centre, resulting in the opening of the 
quinazolinone ring.  This would render the compound susceptible to electrochemical 
oxidation by P450 enzymes forming a reactive metabolite (Figure 48).  
Studies by O’Neill and coworkers showed that interchange of the 3-hydroxyl and 4-
Mannich base side chain in the synthesis of isoquine derivatives inhibits the formation 
of the toxic quinoneimine metabolite of amodiaquine.65 Therefore, the loss of activity 
observed for ortho- (7.1) and meta- (7.2) phenol substituents in SAR 3 may be further 
substantiated by this finding, as this phenomenon is only possible for para-phenols. 
Further reactive metabolite generation, trapping and identification studies would need 


















































Figure 48: Proposed mechanism by which analogue 7.7 undergoes metabolic oxidation to a toxic 
fragment resulting in apparent antimycobacterial growth inhibition. 
3.5. CONCLUSIONS 
The aminoquinazolinone intermediate 7.7 found to possess antimycobacterial activity in 
glycerol-free media formed a basis for structural modifications aimed at preliminary 
SAR exploration. To this end, 11 new analogues were successfully synthesized, 
characterized and evaluated for antimycobacterial activity. All synthesized analogues 
were found to be inactive. This could be explained by the toxic phenol fragment attached 
to the nitrogen, which could undergo metabolic oxidation to form a reactive metabolite 
resulting in apparent activity observed in the assay. These findings therefore suggest 
























CHAPTER 4: SOLUBILITY STUDIES 
4.1. INTRODUCTION 
Solubility plays a major role in biological assays, formulation for in vivo dosing and 
intestinal absorption. It is therefore important to establish the solubility of potential 
drug candidates early on in the drug discovery process.27,68 This enables a determination 
of how feasible it is to perform subsequent in vitro assays as well as detecting possible 
absorption, distribution, metabolism and excretion (ADME) problems early.69 Poorly 
soluble compounds may precipitate out of solution during biological testing leading to 
poorly reproducible and unreliable in vitro and in vivo results.26 Solubility is a 
measurable parameter. However, the reported values obtained are not finite as they are 
dependent on solvent factors (pH, temperature, ionic composition, co-solvent effects) 
and experimental conditions (time, detection method, assay materials) at the time of 
meausurement.68,70  
Different solubility assays have been implemented in drug discovery, each with its own 
strengths and limitations. These assays can be classified as either thermodynamic or 
kinetic solubility. The thermodynamic solubility method follows the addition of aqueous 
solution directly to a solid sample of a compound, therefore the crystal form is 
important as crystal energy must be overcome for dissolution.68,70,7 Incubation times are 
longer (72 hours) to allow equilibrium to be established. Thermodynamic solubility is 
known as the ‘gold standard’ of solubility measurement but it has lower throughput and 
therefore is used later on in drug discovery, typically before First-in-Man studies 
whereby the crystalline form is determined before and after the assay.68,71 In contrast to 
thermodynamic solubility, the kinetic method involves initially dissolving the solid 
compound in an organic solvent [eg. Dimethyl sulfoxide (DMSO)] prior to adding to 
aqueous buffer, which mimics conditions used in biological studies. Since the 
compounds are already dissolved, no crystal energy needs to be overcome. Incubation 
times are shorter (2-4 hours), therefore equilibrium is not established with kinetic 
solubility and the presence of DMSO results in co-solvent effects. Both of these factors 
lead to generally higher solubility values compared to the thermodynamic method but 
results in a higher throughput.68,70,72 
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Two types of solubility experiments were performed on the aminoquinazolinone series, 
both of which were kinetic solubility in nature with the major difference being the 
detection method. The first relies on the appearance of turbidity in solution once a 
compound exceeds its solubility limit in the assay (turbidimetric solubility method). In 
contrast, the alternative method measures the amount of material that has dissolved 
into solution as quantified using HPLC-UV analysis.68,70 The latter approach was adapted 
by our research group as a hybrid method between thermodynamic and kinetic 
solubility whereby DMSO is evaporated off prior to the addition of aqueous buffer to the 
amorphous solid. Removal of DMSO eliminates possible solubility enhancement effects 






Figure 49: General outline of SPR 1 – 5 structures used in the following solubility studies. 
With the intention of fulfilling the aims and objectives of this work, solubility studies 
were performed on all target compounds in order to deduce structural property 
relationships (SPR) with respect to solubility. SPR compounds were selected based on 
SAR 1 – 5 structures as outlined in Figure 49. This chapter therefore describes the 
results of turbidimetric- and HPLC-based solubility methods for synthesized 
aminoquinazolinone derivatives in order to determine whether or not chemical 
modifications aimed at reducing lipophilicity, disrupting molecular planarity/symmetry 
or a combination of strategies enabled optimization of this series with regard to 
solubility. Changes in physicochemical parameters such as ClogP, topological polar 
surface area (tPSA), melting point and calculated dihedral angles were examined in 
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4.1.1. TURBIDIMETRIC SOLUBILITY ASSAY 
Turbidimetric solubility assays were performed in 96-well microtiter plates and 
involved dissolving the target compounds in DMSO to obtain stock solutions of 10 mM, 
from which serial dilutions were prepared in a pre-dilution plate with DMSO to obtain 
concentrations from 0 – 10 μM in triplicate. Secondary dilutions were made in both 
DMSO and phosphate buffered saline (PBS) (pH 7.4) solutions to achieve final 
concentrations ranging from 0 to 200 μM and allowed to incubate at room temperature 
for 2 hours. As the concentration of the testing compound increases in the PBS media, 
precipitation should increase accordingly and causes turbidity, as most organic 
compounds are not freely soluble in aqueous media. Turbidity was detected by 
measuring the absorbance at 620 nm and the approximate solubility determined by 
plotting concentration against corrected absorbance. The limit of solubility was then 
indicated by the concentration value at which the absorbance in the PBS solution rises 
above the DMSO baseline, and reported as a range.74,75 
Two controls are used to validate the turbidimetric solubility assay, a highly soluble 
control (hydrocortisone) and an insoluble control (reserpine). This is indicated by the 
corrected absorbance versus concentration plots of these compounds whereby 
hydrocortisone appears to be soluble across the entire test concentration range (Figure 
50) in contrast to reserpine which displays poor solubility with the PBS curve deviating 
from the DMSO baseline in the 1 – 5 μM range (Figure 51). 
The general classification of solubility ranges for organic compounds using the 
turbidimetric solubility assay is defined as follows:75 
➢ High:  > 100 µM 
➢ Moderate:  20 – 100 µM 


























Figure 51: Absorbance versus concentration curve of the insoluble control, reserpine. 
4.1.2. HPLC-BASED SOLUBILITY ASSAY 
An alternative, more accurate method was additionally used to determine the aqueous 
solubility of compounds, which incorporates elements of kinetic and thermodynamic 
solubility in a hybrid method. This involved using the DMSO-dry down method, adapted 
from Zhou et al.69 Briefly, the high and medium calibration standards (220µM, 100µM) 
in duplicate, as well as the samples (200µM) in triplicate, were added to a 96-well plate, 
from a 10mM stock solution in DMSO. DMSO was then evaporated from the samples for 
2 hours. DMSO was added to the standards and after vortexing the plate, the high 
standard was used to prepare a low (11µM) calibration standard in DMSO. Phosphate 
buffered saline (pH 7.4) was added to the sample wells and the plate was incubated for 




















































and the supernatants transferred to another plate for analysis. Aqueous solubility was 
determined from UV peak areas of the samples relative to the standards using best-fit 
calibration curves.73 
The general classification of solubility ranges for organic compounds using the kinetic 
solubility method is defined as follows: 
➢ High:  > 150 µM 
➢ Moderate:  50 – 150 µM 
➢ Low:   11 – 50 µM 
➢ Very Low:  < 11 µM 
Since calibration standards are used in the kinetic solubility assay at concentrations of 
11, 100 and 220 µM, values below 11 µM and above 220 µM are not well defined and 
therefore compounds outside of these ranges should be considered poorly or highly 
soluble, respectively. If the difference in solubility between two compounds were below 
15% then their solubilities are comparable. However, solubility values between two 
compounds may be distinguished if they have a significant difference above 15%. 
4.2. SOLUBILITY RESULTS 
Upon overall observation of the differences in results between the turbidimetric and 
HPLC-based methods across the aminoquinazolinone series in Figure 52, it is evident 




































































































Turbidimetric Method HPLC-Based Method
Figure 52: Graph comparing solubility results using the turbidimetric assay (low range values 
shown) and the HPLC-based assay (pH 7.4) across all compounds in the series. 
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Using the lower limit of the turbidimetric solubility range, 18 of the 30 tested 
compounds exhibited higher values than the HPLC method. This discrepancy could be 
due to the shorter incubation period of the turbidimetric method, which means that 
measurements are performed on a saturated solution rather than a solution that has 
reached equilibrium.68,70 Additionally, turbidimetric and HPLC-assays differ in the 
identity of the precipitate formed at equilibrium (amorphous or crystalline) as solubility 
is influenced by the solid state form of a compound. The turbidimetric method tends to 
favour amorphous precipitates due to the presence of DMSO whereas the longer 
incubation time and absence of DMSO in the HPLC-based assay favours the form that is 
more energetically favoured. If an amorphous solid is precipitated in the HPLC-based 
assay, then the results are likely to be closer to the turbidimetric method than if a 
crystalline precipitate is formed.72 The large differences between the assays for these 
compounds may therefore suggest that crystalline material is being formed in the HPLC-
assay. Further investigation into this phenomenon would need to be carried out. Since 
the HPLC-method is more rigorous, the following SPR analysis of the 
aminoquinazolinone series will be deduced using the HPLC-based solubility results.  
Various calculated and/or measured structural parameters can be used to explain the 
factors responsible for any improved solubility. As mentioned previously, ClogP is a 
measure of lipophilicity whereby addition of hydrophilic groups reduces lipophilicity, 
therefore lowering the ClogP value.26 tPSA is defined as the sum of polar atoms in a 
molecule.  This property is commonly used to predict intestinal absorption, blood-brain 
barrier penetration and Caco-2 monolayer permeation but is used as a relative 
estimation of polarity to determine the influence of this property on aqueous solubility 
for this chapter.76 The measured melting point property is indicative of crystal lattice 
energy, wherein more stable, tightly packed crystal structures will have higher melting 
points and generally decrease the solubility of the compound.25 Where appropriate, 
dihedral angles between biaryl moieties were obtained by means of density functional 
theory (DFT) calculations (B3LYP) using the software Maestro to determine the degree 
of distortion away from planarity.  
The above parameters are incorporated in the following discussion to aid in the 
interpretation of the solubility data and to determine whether or not the theoretical 
solubility improvement strategies are experimentally validated.  
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4.2.1. SPR 1 SOLUBILITY STUDIES 
SPR analysis of SPR 1 compounds can be divided into three general groups of 
compounds based on their Ar substituents: the sulfones, morpholino and amide 
derivatives (Table 9). 













  pH 7.4 (µM) 













5 – 10 66 4.13 92.83 245.1 – 248.2 
11 
(JA038) 




Y = CH, X = O 20 – 40 56 3.81 88.23 273.0 – 277.9 
5.5 
(JA019) 
Y = CH, X = S 10 – 20 46 4.54 79.00 263.5 – 271.2 
5.6 
(JA020) 
Y = CH, X = NMe >200 51 4.37 82.24 232.1 – 236.3 
5.7 
(JA021) 
Y = N, X = O >200 8 2.71 100.59 239.0 – 246.8 
5.8 
(JA017) 
 Y = CH, 
R = H, R' = H 
40 – 80 34 3.69 101.78 295.5 – 299.9 
5.9 
(JA022) 
Y = CH, 
R = H, R' = Me 
20 – 40 <5 3.90 87.79 292.5 – 298.0 
5.10 
(JA023)  
Y = N, 
R = H, R' = Me 




Y = CH, 
R = R’ = Me 
10 – 20 46 3.64 79.00 286.0 – 288.9  
9.6 
(JA039)   









a Calculated Log P, determined using ChemBioDraw Ultra 14.0 
b Topolological polar surface area, calculated using ChemBioDraw Ultra 14.0 


















Analysis of the sulfonyl analogues generally depicts data in the low to moderate 
solubility range, which is to be expected since the frontrunner compounds previously 
showed low solubility. Transformation of the sulfone 5.1 to the more strongly H-
bonding sulfoxide group 5.2 resulted in no improvement in aqueous solubility. 
However, replacement of the sulfonylmethyl substituent for a cyclopropyl moiety (5.3) 
resulted in a 13-fold solubility enhancement using the HPLC-based method. The 
addition of a methyl substituent in the ortho-position (11) resulted in moderate 
improvement in solubility owing to disruption of planarity through the increase of the 
dihedral angle between the biaryl systems of 11 (50.6°) compared to the parent 
analogue 5.1 (33.9°), as indicated in the computational models depicted in Figure 53. 
The results obtained were not as significant as expected possibly due to the introduction 







Figure 53: Computational models of 5.1 and 11 indicating calculated dihedral angles (centre) with 
90° angle views (right) using Maestro. 
The introduction of morpholino-type structures was beneficial, with an overall 
improvement in solubility observed compared to the parent sulfinyl compound 5.2. This 
could be attributed to the introduction of water solubilizing H-bonding groups as well as 
the incorporation of saturated ring systems to reduce molecular planarity and disrupt 
crystal-stacking capability as indicated by the decrease in melting points relative to 5.2. 
Of the phenyl analogues, the morpholino-derivative 5.4 displayed the most improved 
aqueous solubility (56 µM). The thiomorpholine (5.5) and methylpiperazine (5.6) 
derivatives displayed comparable, moderate solubility whilst incorporation of an 





















The amide analogues generally displayed low solubility. The strategy for this series was 
the addition of ionizable, hydrophilic groups to reduce lipophilicity. The solubility trend 
follows NMe2 (5.11) > NH2 (5.8) > NHMe (5.9), which is reflected in the order of 
increasing lipophilicity (ClogP). Transition from the phenyl secondary amide 5.9 to the 
pyridinyl derivative 5.10 resulted in significant enhancement of aqueous solubility 
owing to the reduction in lipophilicity (from ClogP = 3.90 to ClogP = 3.15). 
Transformation to the carboxylic acid moiety made no significant improvement, 
maintaining values in the low solubility range. The melting points across the amide 
derivatives are relatively similar to the frontrunner compounds. This suggests that the 
apparent improvements in solubility are due to lipophilic properties and not disruption 
of molecular planarity and symmetry for this series of compounds 
4.2.2. SPR 2 SOLUBILITY STUDIES 
The main strategy for SPR 2 analogues was the incorporation of saturated rings in the 
R1 position in order to reduce crystal-packing capabilities, which in turn, should result in 
improved solubility (Table 10).  













pH 7.4 (µM) 








>200 >200 0.85 88.23 214.2 – 217.2 
9.3 
(JA055)  




>200 15 1.06 101.78 328.1 – 333.2 
9.5 
(JA045)  
>200 >200 1.36 79.00 235.7 – 237.8 
a Calculated Log P, determined using ChemBioDraw Ultra 14.0 
b Topolological polar surface area, calculated using ChemBioDraw Ultra 14.0 














The anticipated improvements were observed, particularly for compounds 9.1, 9.2 and 
9.5, displaying high solubility (>200 µM) in both assays. Table 10 indicates that the 
HPLC-method results differ from those of the turbidimetric assay in that compounds 9.3 
and 9.4 showed values in the low solubility range (39.3 µM and 15.3 µM, respectively).  
Comparing 9.3 to 9.5, 9.3 was predicted to be relatively more lipophilic (ClogP = 1.96) 
relative to 9.5 (ClogP = 1.36). Therefore it was expected to have a lower solubility than 
9.5 albeit the two compounds have melting points in the same range. Whereas with 9.4, 
despite the lowered lipophilicity, the melting point is the highest of this series 
suggesting tighter packing. 
To confirm the factors contributing to improved solubility for the saturated analogues, 
ClogP, tPSA and melting point were examined. All compounds showed reduced 
hydrophobicity (ClogP) and melting point parameters compared to 5.2 with increased 
polarity (tPSA). Therefore, improvement of solubility can be ascribed to 2 factors in this 
case: decrease of lipophilicity and disruption of molecular planarity to reduce crystal 
packing ability, which results in lower melting, more soluble compounds.   
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4.2.3. SPR 3 – 5 SOLUBILITY STUDIES 
Upon exploring the aminoquinazolinone intermediates for in vitro antimycobacterial 
activity in glycerol-free media, 12 new intermediate derivatives were synthesized and 
subsequently tested for their solubility. Table 11 summarizes the solubility results 
obtained for SPR 3 – 5.  
Table 11: Apparent aqueous solubility results and physicochemical parameters for 















pH 7.4 (µM) 




   
 10 – 20 <5 4.03 91.23 317.8 – 322.4 
7.1 
(JA060) 






















40 – 80  25 4.03 91.23 193.4 – 200.1 
7.9 
(JA069) 













































10 – 20  11 2.88 61.69 314.6 – 318.1 
a Calculated Log P, determined using ChemBioDraw Ultra 14.0 
b Topolological polar surface area, calculated using ChemBioDraw Ultra 14.0 
c Melting point, recorded on Stuart SMP40 automatic melting point apparatus 
 
Overall, a slight improvement in aqueous solubility was observed across all three series 
compared to the parent compound 7.7, which was poorly soluble (<5 µM). Exploring the 
different regioisomers of the phenol moiety in SPR 3, the ortho-derivative (7.1) was 
found to be highly soluble, with a 30-fold increase in solubility, whilst the meta-isomer 
(7.2) showed no improvement in solubility. Calculated dihedral angles for the three 
derivatives (Figure 54) revealed comparable distortions from planarity (approximately 
70°). Therefore disruption of molecular planarity is not likely to be the reason for 
improved solubility. However, compound 7.1 did display reduced lipophilicity (ClogP = 
3.86) as well as lowered melting point (MP = 186.1 – 190.1°C) than those of 
corresponding meta- and para-derivatives. These results suggest that disruption of 
molecular symmetry accounts for the decrease in crystal packing energy and lowered 
melting point, leading to increased solubility. 
The removal of aromaticity approach was additionally explored in this series with 
compound 7.3. This saturated ring derivative displayed poor solubility with no 
significant decrease in melting point. These results suggest that the crystal packing in 
this molecule is dramatically different despite expecting 7.3 to be more soluble; the 











Substitution of the hydroxyl moiety (7.7) for an amino group (7.4) resulted in no change 
in solubility. All SPR 3 derivatives, except 7.1, displayed poor solubility in the HPLC-
method, with values comparable to the parent compound (<11 µM) and is reflected in 






















Figure 54: Computational models of SAR 3 analogues showing the calculated dihedral angle between 
the phenol moiety and the quinazolinone core. 
The exploration of regioisomers of the bromo substituent on the aminoquinazolinone 
core in the SPR 4 series revealed moderate improvement when the bromo substituent 
was placed in the 4-position (7.8). Derivation of the structural parameters (Table 11) of 
7.8 and 7.9 reveals similar values across properties as the parent compound 7.7, except 
the melting point of 7.8 is marginally lower. This suggests that the bromo substituent in 
the 4-position contributes to disruption of the crystal packing ability to produce a lower 
melting, more soluble compound. 
In the final series, SPR 5 (Figure 49), wherein the R3 position was explored, the mono-
acetylated derivative 12.1 exhibited the most improvement in solubility using the HPLC-
































product (12.2) showed low solubility whilst all other SPR 5 derivatives displayed no 
significant improvement in aqueous solubility. Both acetylated products, 12.1 and 12.2, 
have reduced lipophilicity and melting point parameters compared to 7.7.  
Attempts at including aryl substituents into the R3 position proved to be detrimental to 
solubility as compounds 12.3 and 12.4 exhibited poor solubility in both assays, 
presumably due to the low polarity observed for these compounds (tPSA = 41.46 and 
61.69). 
4.3. PHYSICOCHEMICAL PROPERTIES 
In an attempt to understand the factors responsible for improved aqueous solubility, the 
physicochemical parameters and log (HPLC-based solubility) in Tables 9 – 11 were 
plotted. Evan’s guidelines were used to determine the degree of correlation strength (R2 
value):77 
0.0 – 0.19:  Very weak 
0.2 – 0.39:  Weak 
0.4 – 0.59:  Moderate 
0.6 – 0.79:  Strong 




















Figure 55: Relationship between solubility and ClogP data of SPR 1 - 5. 
 



















As shown in Figure 55, ClogP was very weakly but negatively correlated to log 
(solubility) with an R2 value of 0.07. As expected, the relationship between ClogP and 
solubility is not direct because for these compounds, the changes in dihedral angle and 
crystal packing especially have a greater influence than a simple reduction or increase in 
ClogP. However, it was noted that of the five least lipophilic compounds, three were in 
the most soluble class and therefore is indicative that reduced lipophilicity is a 














Figure 56: Relationship between solubility and tPSA data of SAR 1 - 5.  
 
Figure 56 shows that tPSA was found to have little to no correlation with solubility (R2 = 
0.01). There are many drastic structural changes around the aminoquinazolinone core 
scaffold across SPR 1- 5. As such, a combination of factors contributes to the apparent 
reduction or enhancement of solubility.  
In contrast to the limitations of the aforementioned physicochemical correlations, the 
melting point parameter was found to be the most strongly correlated with aqueous 
solubility (R2 = 0.43).  






























Figure 57: Relationship between solubility and melting point data of SAR 1 - 5. 
 
The moderate relationship between melting point and log (solubility) observed in 
Figure 57 suggests that the crystal packing efficiency of the compounds in its crystal 
lattice is more dominant than changes in lipophilicity or polarity. These results imply 
that disruption of molecular planarity and/or symmetry by removal of aromaticity or 
introduction of substituents in the ortho-position decreases crystal packing energy so as 
to lower the melting point, leading to increased solubility.  This strong, negative 
correlation between melting point and solubility is supported by previous reports 
wherein high solubility was shown to be associated with reduced melting points.71,78–80  
Overall, log (solubility) was most correlated with melting point than ClogP and tPSA 
factors. In other words, these analyses suggest that melting point can be considered as 
an applicable parameter for aqueous solubility of aminoquinazolinone compounds 
described above.  
























In summary, 30 compounds were synthesized and analysed for their kinetic solubility 
using turbidimetric and HPLC-based methods. Physicochemical parameters were 
included in order to deduce the possible factors responsible for any improvement in 
solubility. Overall, the turbidimetric method was found to be over-estimating solubility 
compared to the HPLC-based method. However, similar trends were still observed for 
compounds in relation to one another. The relative aqueous solubility trends of SPR 1 









Figure 58: Summary of aqueous solubility trends observed for SPR 1 and SPR 2 series’ based on 
values obtained using the HPLC-method. 
In SPR 1, a moderate improvement in solubility was evident for the morpholino and 
amide series compared to the front-runner compounds 5.1 and 5.2. Introducing a 
methyl substituent in the ortho-position (11) was found to be a successful approach 
toward increasing the dihedral angle and, in turn, improving aqueous solubility. The 
strategy of removing aromaticity to disrupt planarity and subsequently disturb the 
efficiency of crystal packing to improve solubility was explored in SPR 2. This resulted 
in highly soluble (>200 µM) compounds 9.1, 9.2 and 9.5, which was reflected in the 
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Figure 59 summarizes the trends observed between structures of SPR 3 – 5 and 
aqueous solubility. The new aminoquinazolinone intermediates generally displayed 
poor to moderate solubility. The most promising analogue, however, was the ortho-
phenol derivative 7.1, which was shown to be highly soluble (156 µM) owing to the 








Figure 59: Summary of aqueous solubility trends observed for SPR 3 – 5 based on values obtained 
using the HPLC-method. 
Analysis of the relationships between solubility and physicochemical properties (ClogP, 
tPSA and MP) were performed. As shown in Figure 57, melting point was most 
moderately correlated with solubility (R2 = 0.43), suggesting that melting point can be 
considered as a parameter for the aqueous solubility of 2-aminoquinazolinones that 
were modified in ways that disrupted molecular symmetry and planarity. 
In general, the results obtained suggest that the chemical modifications employed, 
particularly introduction of substituents to modify the dihedral angle and saturation of 
aromatic rings to disrupt molecular planarity and symmetry, were effective at 
improving the aqueous solubility of the aminoquinazolinone series. A combination of 
these approaches with the conventional approach of reducing lipophilicity may be 






























CHAPTER 5: SUMMARY AND FUTURE PROSPECTS 
5.1. GENERAL SUMMARY AND CONCLUSIONS 
 
A series of 2-aminoquinazolinones designed to improve solubility were successfully 
synthesized. Substituents were selected to reduce lipophilicity by introducing 
hydrophilic moieties or to disrupt molecular planarity/symmetry by reducing 
aromaticity or increasing the dihedral angle. Adapted synthetic routes were employed to 
deliver the desired analogues. All synthesized compounds were characterized by 1H-









Figure 60: Summary of antimycobacterial activity trends observed for SAR 1 derivatives in GAST Fe 
media. 
 
SAR 1 derivatives were evaluated for in vitro antimycobacterial activity in GAST Fe and 
7H9 ADC media, as well as for cytotoxicity and metabolic stability. The following 
conclusions from the in vitro results were drawn: 
✓ All compounds, except 5.7 and 9.6, exhibited promising antimycobacterial 
activity (MIC99 <10 μM) in glycerol-containing media against the H37Rv strain of 
Mtb (Figure 60). 
✓ Of the 11 compounds that were evaluated for cytotoxicity, 8 of them displayed 
low cytotoxicity. 
✓ Derivatives displayed good metabolic stability in liver microsomes across three 
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Figure 61: General structure of inactive SAR 1 and SAR 2 derivatives tested in glycerol-free media. 
The disconnect between in vitro and in vivo results on frontrunner compounds 5.1 and 
5.2 was investigated. In this regard, subsequent in vitro assays were performed on SAR 
1 and SAR 2 intermediates and target compounds in glycerol-free media (Figure 61). All 
derivatives, except one intermediate 7.7, were inactive. SAR was thus explored around 
this intermediate but no substantial activity was observed for the new analogues (Figure 











Figure 62: Summary of antimycobacterial SAR 3 – 5 results tested in glycerol-free media displaying 















Solubility studies were performed on 30 synthesized target compounds of SPR 1 – 5. 
Turbidimetric and HPLC-based assay methods were used for solubility analysis and the 
following conclusions were deduced: 
✓ The turbidimetric assay generally over-estimated solubility. 
✓ Introduction of hydrophilic Ar substituents resulted in moderate improvement in 
solubility. 
✓ Introduction of a substituent in the ortho-position to disrupt molecular planarity 
and symmetry resulted in 10-fold improvement in the solubility of 11 relative to 
the parent analogue 5.1 and was accompanied by an increase in the calculated 







Figure 63: Solubility results of ortho-substituted analogue 11 compared to frontrunner compound 
5.1. 
 
✓ Saturated ring systems of SPR 2 analogues displayed the most promising results 
with 3 out of the 5 SPR 2 compounds showing high solubility (>200 µM). 
Reduction in crystal packing energy due to disruption of planarity was confirmed 

































MP: 221 - 224°C
9.2
Solubility: >200 mM
MP: 214 - 217°C
9.5
Solubility: >200 mM





















✓ SPR 3 – 5 compounds showed poor to moderate solubility albeit the ortho-
phenol derivative was found to be highly soluble due to disruption of molecular 









Figure 65: Structure of ortho-phenol analogue displaying high solubility compared to 7.7 owing to 
disruption of molecular symmetry. 
 
✓ Relationships between solubility and the physicochemical parameters (ClogP, 
tPSA and melting point) were deduced. Melting point was found to be the most 
correlated with solubility suggesting that changes in crystal packing efficiency is 
more dominant than changes in lipophilicity for this series. 
5.2. FUTURE OUTLOOK AND RECOMMENDATIONS 
 
- Since the mechanism of action of the 2-aminoquinazolinone series was found to 
be glycerol-dependent, it is recommended that this mechanism be thoroughly 
investigated.  
- Since selected compounds showed good cytotoxicity, metabolic stability and in 
vivo DMPK profiles, they should be explored in other disease models.  
- In order to determine whether or not the mechanism of inhibition of the growth 
of Mtb by intermediate 7.7 is occurring via the proposed formation of a reactive 
metabolite, reactive metabolite generation, trapping and identification studies 
should be undertaken. 
- Further exploration of the X-ray crystal structure of saturated derivatives (SPR 
2) and ortho-substituted analogues (7.1 or 11) should be undertaken in order to 























MP: 186 - 190°C
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CHAPTER 6: EXPERIMENTAL RESULTS 
6.1. MATERIALS AND EQUIPMENT 
All commercially available chemicals were purchased from Sigma-Aldrich, Merck or 
Combi-Blocks Limited and were of analytical grade, thus used without further 
purification. Reactions were monitored by thin layer chromatography (TLC) using Fluka 
or Merck F254 aluminium-backed pre-coated silica gel plates and were visualized under 
ultraviolet light at 254 or 366 nm. Silica gel column chromatography was performed 
using Merck kieselgel 60: 70-230 mesh by gravity column chromatography or by flash 
chromatography on a Biotage Isolera™ system (Biotage AB, Uppsala, Sweden). 
Reported compounds were characterized using 1D and 2D 1H NMR, 13C NMR, HPLC-MS 
and melting point determination.  
1H NMR spectra were recorded on a Varian Mercury (300 MHz), a Bruker Ultrashield-
Plus (400 MHz) spectrometer or a Bruker (600 MHz). 13C NMR spectra were recorded 
on the same instruments at 101 MHz or 151 MHz. NMR samples were dissolved in 
deuterated dimethylsulfoxide (DMSO-d6) or chloroform (CDCl3). Chemical shifts (δ) are 
reported in parts per million (ppm) to 2 decimal places. Coupling constants (J) are 
reported in Hertz (Hz) to one decimal place. Abbreviations used in assigning lH-NMR 
signals are: s (singlet), d (doublet), dd (doublet of doublets), ddd (doublet of doublet of 
doublets), t (triplet), td (triplet of doublets), q (quartet), or m (multiplet). 
Target compounds’ peak purities and mass spectrometry were determined on an Agilent 
HPLC system equipped with Agilent 1260® Infinity Binary Pump, Agilent 1260® 
Infinity Diode Array Detector, Agilent 1290® Infinity Column Compartment, Agilent 
1260® Infinity Autosampler, Agilent 6120® Quadrupole LC/MS and Peak Scientific® 
Genius 1050 Nitrogen Generator. The column used was an X-bridge® C18, 2.5 μm, 3.0 
mm (ID) x 50 mm (length) maintained at 35 °C. The injection volume was 2 μL while the 
mass spectra were obtained both by positive mode Electron Spray ionization (ESI) and 
Atmospheric Pressure Chemical Ionization (APCI). The diode array detector was 
programmed to scan the eluents at an absorption wavelength range of 210-640 nm.  
Melting points were determined using a Stuart SMP40 automatic melting point 
apparatus and are uncorrected.  
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6.2. SYNTHESIS AND CHARACTERIZATION 
6.2.1. GENERAL PROCEDURES AND CHARACTERIZATION FOR SAR 1 INTERMEDIATE 
COMPOUNDS 1 – 4 
6-Iodo-2-thioxo-3-(4-(trifluoromethyl)phenyl)-2,3-dihydroquinazolin-4(1H)-one (1) 
2-amino-5-iodobenzoic acid (5.08 g, 19.30 mmol, 1.0 Eq) and 1-isothiocyanato-4-
(trifluoromethyl)benzene (4.12 g, 20.26 mmol, 1.05 Eq) were dissolved in dioxane   
(74.5 mL) and treated with triethylamine (3.8 mL, 1.5 Eq). The solution was refluxed for 
4 hours, cooled to room temperature, and the solids that formed were filtered. The 
solids were resuspended in diethyl ether (Et2O) and filtered again to afford the thioxo-
quinazolinone intermediate. 
 White solid (7.84 g, 91%); m.p. 296 – 300°C; Rf 
(EtOAc:Hex, 3:7) 0.37; 1H NMR (300 MHz, DMSO-d6) δ 
13.18 (s, 1H, H6), 8.20 (d, J = 1.9 Hz, 1H, H1), 8.10 (dd, J 
= 8.6, 2.0 Hz, 1H, H2), 7.88 (d, J = 8.3 Hz, 2H, H5), 7.56 
(d, J = 8.1 Hz, 2H, H4), 7.26 (d, J = 8.6 Hz, 1H, H3); 13C 
NMR (101 MHz, DMSO-d6) δ 176.14, 159.02, 144.21, 
143.32, 139.64, 135.69, 130.72 (2C), 126.60 (2C), 
126.56, 118.77, 118.54, 88.18, 66.84; HPLC-MS (APCI/ESI): Purity > 99%, tR = 4.452 min, 
m/z [M+H]+
 
= 448.9.  
2-Chloro-6-iodo-3-(4-(trifluoromethyl)phenyl)quinazolin-4(3H)-one (2) 
PCl5 (6.3 g, 30.26 mmol, 1.73 Eq) was added in one portion to a mixture of 1 (7.84 g,  
17.5 mmol, 1.0 Eq) in POCl3 (38.8 mL, 417.7 mmol, 23.88 Eq) at room temperature 
(24.4°C). The mixture was stirred for 15 minutes at 24.4°C and was subsequently heated 
at 110°C for 14 hours under nitrogen. The reaction was cooled to room temperature, 
concentrated in vacuo and then diluted with ethyl acetate to be added portionwise to 
stirred ice – saturated sodium bicarbonate and stirred until all solids dissolved. The 
organic layer was then separated, washed with brine, dried over magnesium sulphate 
and concentrated under reduced pressure. The resulting residue was triturated in Et2O 





















 Off-white solid (6.26 g, 79%); m.p. 200 – 204°C; Rf 
(EtOAc:Hex, 3:7) 0.69; 1H NMR (300 MHz, DMSO-d6) δ 
8.39 (d, J = 1.8 Hz, 1H, H1), 8.22 (dd, J = 8.5, 2.1 Hz, 1H, 
H2), 7.99 (d, J = 8.3 Hz, 2H, H5), 7.81 (d, J = 8.2 Hz, 2H, 
H4), 7.52 (d, J = 8.7 Hz, 1H, H3); 13C NMR (101 MHz, 
DMSO-d6) δ 150.20, 143.82, 139.91, 135.86, 135.42, 
130.71 (2C), 130.44, 129.22, 127.13 (2C), 126.41, 118.23, 116.99, 85.69; HPLC-MS 
(APCI/ESI): Purity = 90%, tR = 4.567 min, m/z [M+H]
+ 
= 450.9.  
6-Iodo-2-((4-methoxybenzyl)amino)-3-(4-(trifluoromethyl)phenyl)quinazolin-4(3H)-one (3) 
4-Methoxybenzylamine (2.36 mL, 18.06 mmol, 1.3 Eq) and N,N-diisopropylethylamine 
(DIPEA) (4.84 mL, 27.8 mmol, 2.0 Eq) were dissolved in DMF and 2 (6.26 g, 13.9 mmol, 
1.0 Eq) was added portionwise. The reaction was stirred for 4 hours at 80°C and allowed 
to cool to room temperature. The solvent was concentrated under reduced pressure and 
diluted with ethyl acetate. The organic phase was washed with 5% lithium chloride (x5), 
brine (x3), dried over magnesium sulphate and concentrated in vacuo. 
Brown solid (6.36 g, 83%); m.p. 172 – 175°C; Rf 
(EtOAc:Hex, 3:7) 0.46; 1H NMR (300 MHz, 
DMSO-d6) δ 8.15 (d, J = 2.0 Hz, 1H, H1), 7.97 (d, J 
= 8.3 Hz, 2H, H5), 7.87 (dd, J = 8.6, 2.2 Hz, 1H, 
H2), 7.67 (d, J = 8.1 Hz, 2H, H4), 7.24 (d, J = 8.7 
Hz, 2H, H8), 7.11 (d, J = 8.7 Hz, 1H, H3), 6.85 (d, J 
= 8.7 Hz, 2H, H9), 6.68 (t, J = 5.9 Hz, 1H, H6), 
4.44 (d, J = 5.9 Hz, 2H, H7), 3.71 (s, 3H, H10); 13C 
NMR (101 MHz, DMSO-d6) δ 161.00, 158.55, 150.59, 149.58, 143.08, 139.05, 134.95, 
132.01, 130.97 (2C), 130.70, 130.14 (q, J = 32.0 Hz, 1C, C-CF3), 128.88 (2C), 124.7 (q, J = 
272.5 Hz, 1C, CF3), 127.75 (2C), 127.60, 119.49, 114.00 (2C), 84.74, 44.18; HPLC-MS 
















































Compound 3 (6.35 g, 11.52 mmol, 1.0 Eq) was dissolved in TFA (56.2 mL, 63.7 Eq) and 
refluxed at 80°C for 72 hours. The reaction was cooled to room temperature and the 
solvent was concentrated. The residue was resuspended in DCM and added portionwise 
to a stirred ice – saturated sodium bicarbonate solution. The organic phase was 
separated, the aqueous phase was extracted with DCM and the combined organic phases 
were diluted with Et2O to a 1:1 ratio DCM/Et2O. The solids were filtered, washed with 
Et2O and dried under vacuum to afford the aminoquinazolinone intermediate 4. 
Pale green solid (4.3404 g, 87%); m.p. 265 – 270°C; Rf 
(EtOAc:Hex, 1:1) 0.26; 1H NMR (300 MHz, DMSO-d6) δ 
8.14 (d, J = 2.0 Hz, 1H, H1), 7.93 (d, J = 8.3 Hz, 2H, H5), 
7.87 (dd, J = 8.7, 2.2 Hz, 1H, H2), 7.63 (d, J = 8.1 Hz, 2H, 
H4), 7.07 (d, J = 8.7 Hz, 1H, H3), 6.60 (s, 2H, H6); 13C 
NMR (101 MHz, DMSO-d6) δ 161.06, 152.21, 150.20, 
143.04, 139.51, 135.01, 130.59 (2C), 130.03, 127.59, 
127.55 (2C), 126.93, 119.24, 84.35; HPLC-MS (APCI/ESI): Purity = 98%, tR = 4.208 min, 
m/z [M+H]
+ 
= 432.0.  
6.2.2. GENERAL PROCEDURE FOR SUZUKI MIYAURA COUPLING REACTION IN THE 
SYNTHESIS OF THE TARGET COMPOUNDS 5.1 – 5.11 
2-Amino-6-iodo-3-(4-(trifluoromethyl)phenyl)quinazolin-4(3H)-one 4 (1.0 Eq) and the 
appropriate arylboronic acid or ester (1.5 Eq) were dissolved in anhydrous 1,4-dioxane 
(1.84 mL) and flushed with nitrogen. Bis(triphenylphosphine)palladium(II) dichloride, 
PdCl2(PPh3)2, (0.1 Eq) was added to the solution, cesium carbonate or potassium 
carbonate (3.0 Eq) was dissolved in water (0.05 Eq) and subsequently added to the 
reaction mixture. The solution was heated at 80°C until TLC monitoring showed 
completion (1-3 hours), allowed to cool to room temperature and diluted with EtOAc to 
be filtered through celite. The organic phase was washed with water and brine, dried 
over magnesium sulphate and concentrated under reduced pressure. The resulting 
crude residue was purified by silica-gel chromatography using the relevant solvent 
system, combined pure fractions were concentrated in vacuo, triturated with Et2O, 





















Obtained from 4 (236.3 mg, 0.55 mmol,  
1.0 Eq), using 3-methylsulfonylphenyl 
boronic acid (164.4 mg, 0.82 mmol,        
1.5 Eq), as a white solid (115.2 mg, 46%); 
m.p 246.3 – 250.4°C; Rf (EtOAc:DCM, 6:4) 
0.35; 1H NMR (400 MHz, DMSO-d6) δ 8.24 
(d, J = 2.2 Hz, 1H, H1), 8.20 (t, J = 1.8 Hz, 
1H, H7), 8.07 (ddd, J = 7.6, 1.8, 1.0 Hz, 1H, H10), 8.06 (dd, J = 8.6, 2.4 Hz, 1H, H2), 7.96 (d, J 
= 8.8 Hz, 1H, H5), 7.90 (ddd, J = 7.8, 1.8, 1.0 Hz, 1H, H8), 7.75 (t, J = 7.8 Hz, 1H, H9), 7.67 (d, 
J = 7.9 Hz, 1H, H4), 7.40 (d, J = 8.6 Hz, 1H, H3), 6.59 (s, 2H, H6), 3.31 (s, 3H, H11); 13C NMR 
(101 MHz, DMSO-d6) δ 162.24, 152.18, 150.88, 142.21, 140.96, 139.69, 133.66, 131.86, 
131.66, 130.64 (2C), 130.17 (q, J = 32.0 Hz, 1C, C-CF3), 127.61, 127.58 (2C), 125.83, 
125.41, 124.96, 124.87, 124.54 (q, J = 272.5 Hz, 1C, CF3), 117.40, 43.95; HPLC-MS 
(APCI/ESI): Purity = 99%, tR = 3.693 min, m/z [M+H]
+ 




Obtained from 4 (210.1 mg, 0.49 mmol, 
1.0 Eq), using 3-methylsulfinylphenyl 
boronic acid (98.6 mg, 0.54 mmol, 1.3 Eq), 
as an off-white solid (85.9 mg, 40%); m.p 
325.5 – 328.3°C; Rf (MeOH:EtOAc, 1:9) 
0.20; 1H NMR (400 MHz, DMSO-d6) δ 8.21 
(d, J = 2.0 Hz, 1H, H1), 8.04 (dd, J = 8.6, 2.4 
Hz, 1H, H2), 7.98 (t, J = 2.2 Hz, 1H, H7), 7.95 (d, J = 8.2 Hz, 2H, H5), 7.87 (dt, J = 6.6, 2.2 Hz, 
1H, H10), 7.72 – 7.64 (m, 4H, H4, H8, H9), 7.38 (d, J = 8.2 Hz, 1H, H3), 6.57 (s, 2H, H6), 2.82 
(s, 3H, H11); 13C NMR (101 MHz, DMSO-d6) δ 162.28, 152.08, 150.68, 147.89, 140.82, 
139.73, 133.64, 132.55, 130.66 (2C), 130.45, 130.14 (q, J = 32.0 Hz, 1C, C-CF3), 128.86, 
127.61, 127.57, 125.34, 124.75, 124.7 (q, J = 272.48 Hz, 1C, CF3), 122.64, 121.49, 117.37, 
43.74; HPLC-MS (APCI/ESI): Purity > 99%, tR = 4.346 min, m/z [M+H]
+ 
















































Obtained from 4 (208.7 mg, 0.48 mmol,  1.0 
Eq), using 3-(cyclopropylsulfonyl)phenyl 
boronic acid (120.5 mg, 0.73 mmol, 1.5 Eq), 
as a pale yellow solid (167.8 mg, 71%);              
m.p 245.1 – 248.2 °C; Rf (EtOAc:Hexane, 
1:1) 0.13; 1H NMR (400 MHz, DMSO-d6) δ 
8.22 (d, J = 2.3 Hz, 1H, H1), 8.14 (t, J = 1.7 
Hz, 1H, H7), 8.10 – 8.06 (m, 1H, H10), 8.05 (dd, J = 8.6, 2.3 Hz, 1H, H2), 7.96 (d, J = 8.3 Hz, 
2H, H5), 7.87 (dt, J = 7.8, 1.1 Hz, 1H, H8), 7.76 (t, J = 7.8 Hz, 1H, H9), 7.67 (d, J = 8.2 Hz, 2H, 
H4), 7.40 (d, J = 8.6 Hz, 1H, H3), 6.60 (s, 2H, H6), 3.01 (m, 1H, H11), 1.21 – 1.15 (m, 2H, 
H12), 1.10 – 1.02 (m, 2H, H12); 13C NMR (101 MHz, DMSO-d6) δ 162.25, 152.20, 150.90, 
141.99, 141.06, 139.70, 133.66, 131.84, 131.66, 130.82, 130.66 (2C), 130.16 (q, J = 32.0 
Hz, 1C, C-CF3), 127.62, 127.58, 126.15, 125.45, 124.94 (2C), 124.57 (q, J = 272.48 Hz, 1C, 
CF3), 117.41, 32.45, 5.93 (2C); HPLC-MS (APCI/ESI): Purity = 98%, tR = 3.974 min, m/z 
[M+H]
+ 
= 486.1.  
2-Amino-6-(3-(morpholine-4-carbonyl)phenyl)-3-(4-(trifluoromethyl)phenyl)quinazolin-
4(3H)-one (5.4) 
Obtained from 4 (202.6 mg, 0.47 
mmol, 1.0 Eq), using 3-
(morpholine-4-carbonyl)phenyl 
boronic acid (165.7 mg, 0.71 
mmol, 1.5 Eq), as a pale yellow 
solid (202.1 mg, 87%); m.p 273.0 – 
277.9 °C; Rf (3% MeOH in EtOAC) 
0.4; 1H NMR (300 MHz, DMSO-d6) δ 8.16 (d, J = 2.2 Hz, 1H, H1), 8.00 (dd, J = 8.6, 2.3 Hz, 
1H, H2), 7.95 (d, J = 8.3 Hz, 2H, H5), 7.79 (dt, J = 7.8, 1.1 Hz, 1H, H10), 7.70 (t, J = 1.5 Hz, 
1H, H7), 7.66 (d, J = 8.1 Hz, 2H, H4), 7.55 (t, J = 7.7 Hz, 1H, H9), 7.38 (dt, J = 6.4, 1.3 Hz, 1H, 
H8), 7.36 (d, J = 8.6 Hz, 1H, H3), 6.56 (s, 2H, H6), 3.62 (m, 4H, H12), 3.47 (m, 4H, H11); 13C 
NMR (101 MHz, DMSO-d6) δ 169.40, 162.28, 151.99, 150.50, 140.04, 139.75, 136.97, 



















































(2C), 126.10, 125.28, 125.15, 124.58, 124.57 (q, J = 272.48 Hz, 1C, CF3), 117.34, 66.54 
(4C); HPLC-MS (APCI/ESI): Purity = 98%, tR = 3.824 min, m/z [M+H]
+ 
= 495.1.  
2-Amino-6-(3-(thiomorpholine-4-carbonyl)phenyl)-3-(4-(trifluoromethyl)phenyl)quinazolin-
4(3H)-one (5.5) 
Obtained from 4 (211.3 mg, 0.49 
mmol, 1.0 Eq), using 3- 
(thiomorpholine-4-carbonyl)phenyl 
boronic acid (184.6 mg, 0.74 mmol, 
1.5 Eq), as a pale yellow solid (208.4 
mg, 83%); m.p 263.5 – 271.2 °C; Rf 
(Hexane:EtOAc, 7:3) 0.15; 1H NMR 
(400 MHz, DMSO-d6) δ 8.17 (d, J = 1.9 Hz, 1H, H1), 8.01 (dd, J = 8.6, 2.4 Hz, 1H, H2), 7.95 
(d, J = 8.2 Hz, 2H, H5), 7.78 (dt, J = 7.9, 1.5 Hz, 1H, H10), 7.70 (t, J = 1.9 Hz, 1H, H7), 7.66 (d, 
J = 8.1 Hz, 2H, H4), 7.55 (t, J = 7.8 Hz, 1H, H9), 7.37 (d, J = 8.9 Hz, 1H, H3), 7.36 (dt, J = 7.6, 
1.3 Hz, 1H, H8), 6.55 (s, 2H, H6), 3.74 (m, 4H, H11), 2.67 (m, 4H, H12); 13C NMR (101 MHz, 
DMSO-d6) δ 169.69, 162.27, 151.98, 150.48, 140.04, 139.74, 137.44, 133.61, 132.88, 
130.65 (2C), 130.13 (q, J = 32.0 Hz, 1C, C-CF3), 129.75, 127.59 (3C), 125.71, 125.26, 
124.79, 124.60, 124.54 (q, J = 272.48 Hz, 1C, CF3), 117.33, 27.24 (4C); HPLC-MS 
(APCI/ESI): Purity = 97%, tR = 4.213 min, m/z [M+H]
+ 
= 511.1.  
2-Amino-6-(3-(4-methylpiperazine-1-carbonyl)phenyl)-3-(4-(trifluoromethyl)phenyl) 
quinazolin -4(3H)-one (5.6) 
Obtained from 4 (205.3 mg, 0.48 
mmol, 1.0 Eq), using 3-(4-methyl 
piperazine-1-carbonyl)phenyl 
boronic acid, pinacol ester (235.9 
mg, 0.71 mmol, 1.5 Eq), as a 
brown-white solid (76.8 mg, 
32%); m.p 232.1 – 236.3 °C; Rf 
(5% MeOH in EtOAC) 0.13; 1H NMR (300 MHz, DMSO-d6) δ 8.15 (d, J = 2.3 Hz, 1H, H1), 
8.00 (dd, J = 8.6, 2.4 Hz, 1H, H2), 7.95 (d, J = 8.3 Hz, 2H, H5), 7.78 (dt, J = 8.0, 1.2 Hz, 1H, 
H10), 7.63 – 7.70 (m, 3H, H4, H7), 7.54 (t, J = 7.7 Hz, 1H, H9), 7.36 (d, J = 8.6 Hz, 1H, H3), 























































(s, 3H, H13); 13C NMR (101 MHz, DMSO-d6) δ 169.26, 162.28, 151.98, 150.49, 139.99, 
139.74, 137.32, 133.59, 132.91, 130.66 (2C), 129.71, 127.69 (2C), 127.58, 127.55, 
125.99, 125.29, 124.96, 124.55, 117.33, 54.95 (2C), 46.06; HPLC-MS (APCI/ESI): Purity = 
99%, tR = 3.041 min, m/z [M+H]
+ 
= 508.2.  
2-Amino-6-(5-(morpholine-4-carbonyl)pyridin-3-yl)-3-(4-(trifluoromethyl)phenyl) 
quinazolin-4(3H)-one (5.7) 
Obtained from 4 (206.3 mg, 0.48 
mmol, 1.0 Eq), using N-
(morpholine-4-carbonyl)pyridine-
3-boronic acid, pinacol ester (228.4 
mg, 0.72 mmol, 1.5 Eq), as a white 
solid (117.6 mg, 50%); m.p 239.0 – 
246.8 °C; Rf (2% MeOH in EtOAC) 
0.2; 1H NMR (400 MHz, DMSO-d6) δ 9.00 (d, J = 2.3 Hz, 1H, H8), 8.59 (d, J = 2.0 Hz, 1H, 
H9), 8.23 (d, J = 2.3 Hz, 1H, H1), 8.14 (t, J = 2.1 Hz, 1H, H7), 8.06 (dd, J = 8.6, 2.3 Hz, 1H, 
H2), 7.96 (d, J = 8.7 Hz, 2H, H5), 7.67 (d, J = 8.6 Hz, 2H, H4), 7.39 (d, J = 8.6 Hz, 1H, H3), 
6.61 (s, 2H, H6), 3.65 (m, 4H, H11), 3.43 (m, 4H, H10); 13C NMR (101 MHz, DMSO-d6) δ 
167.20, 162.16, 152.22, 150.97, 148.46, 146.47, 139.68, 135.07, 133.69, 132.58, 132.17, 
130.64 (2C), 130.30, 129.98, 129.73, 127.61, 127.57 (2C), 125.91, 125.44, 125.17, 





Obtained from 4 (208.1 mg, 0.48 mmol, 
1.0 Eq), using 3-aminocarbonylphenyl 
boronic acid (119.5 mg, 0.72 mmol, 1.5 
Eq), as a pale yellow solid (51.6 mg, 
25%); m.p 295.5 – 299.9°C; Rf (5% MeOH 
in EtOAC) 0.3; 1H NMR (300 MHz, DMSO-
d6) δ 8.23 (d, J = 2.2 Hz, 1H, H1), 8.20 (s, 
1H, H7), 8.16 (s, 2H, H11), 8.03 (dd, J = 8.6, 2.3 Hz, 1H, H2), 7.95 (d, J = 8.3 Hz, 2H, H5), 7.86 
(d, J = 7.8 Hz, 1H, H10), 7.85 (d, J = 7.6 Hz, 1H, H8), 7.67 (d, J = 8.1 Hz, 2H, H4), 7.55 (t, J = 

















































δ 168.26, 162.32, 151.96, 150.44, 139.81, 137.85, 135.52, 133.66, 133.16, 130.67 (2C), 
129.51, 129.40, 128.09, 127.56, 126.77, 126.67, 125.68, 125.24, 124.65, 124.54, 117.36; 
HPLC-MS (APCI/ESI): Purity = 98%, tR = 4.263 min, m/z [M+H]
+ 
= 425.1.  
3-(2-Amino-4-oxo-3-(4-(trifluoromethyl)phenyl)-3,4-dihydroquinazolin-6-yl)-N-methyl 
benzamide (5.9) 
Obtained from 4 (206.8 mg, 0.48 
mmol, 1.0 Eq) using 3-(N-methylamino 
carbonyl) phenylboronic acid (128.8 
mg, 0.72 mmol, 1.5 Eq), as a white 
solid (57.3 mg, 27%); m.p 292.5 – 
298.0 °C; Rf (100% EtOAc) 0.15; 1H 
NMR (400 MHz, DMSO-d6) δ 8.58 (q, J 
= 3.9 Hz, 1H, H11), 8.23 (d, J = 2.2 Hz, 1H, H1), 8.16 (t, J = 1.8 Hz, 1H, H7), 8.02 (dd, J = 8.6, 
2.3 Hz, 1H, H2), 7.96 (d, J = 8.2 Hz, 2H, H6), 7.84 (m, 1H, H10), 7.82 (m, 1H, H8), 7.67 (d, J = 
7.8 Hz, 2H, H5), 7.56 (t, J = 7.7 Hz, 1H, H9), 7.38 (d, J = 8.6 Hz, 1H, H3), 6.55 (s, 2H, H4), 
2.83 (d, J = 4.5 Hz, 3H, H12); 13C NMR (101 MHz, DMSO-d6) δ 166.93, 162.31, 151.96, 
150.44, 139.85, 139.77, 135.72, 133.65, 133.15, 130.66 (2C), 129.56, 129.21, 127.59 
(2C), 127.56, 126.42, 125.23 (2C), 125.21, 124.63, 117.36, 26.71; HPLC-MS (APCI/ESI): 
Purity = 99%, tR = 3.778 min, m/z [M+H]
+ 
= 439.1.  
5-(2-Amino-4-oxo-3-(4-(trifluoromethyl)phenyl)-3,4-dihydroquinazolin-6-yl)-N-methyl 
nicotinamide (5.10) 
Obtained from 4 (218.7 mg, 0.51 
mmol, 1.0 Eq) using 5-(N-
methylcarbamoyl) pyridine-3-boronic 
acid, pinacol ester (199.4 mg, 0.77 
mmol, 1.5 Eq), as an orange-brown 
solid (100.1 mg, 45%); m.p 310.5 – 
313.5 °C; Rf (5% MeOH in EtOAc) 0.15; 
1H NMR (400 MHz, DMSO-d6) δ 9.05 (d, J = 2.2 Hz, 1H, H9), 8.96 (d, J = 2.0 Hz, 1H, H8), 
8.76 (q, J = 5.8 Hz, 1H, H10), 8.47 (t, J = 2.2 Hz, 1H, H7), 8.28 (d, J = 2.3 Hz, 1H, H1), 8.08 
(dd, J = 8.6, 2.3 Hz, 1H, H2), 7.96 (d, J = 8.3 Hz, 2H, H5), 7.71 – 7.65 (d, J = 8.0 Hz, 2H, H4), 

















































MHz, DMSO-d6) δ 172.40, 165.49, 162.20, 152.22, 150.96, 149.69, 147.44, 139.70, 
134.90, 133.62, 132.40, 130.64 (2C), 130.16 (q, J = 32.0 Hz, 1C, C-CF3), 127.62 (2C), 
125.45, 125.18, 124.92 (q, J = 272.48 Hz, 1C, CF3), 117.52, 26.65, 21.50; HPLC-MS 
(APCI/ESI): Purity = 98%, tR = 3.351 min, m/z [M+H]
 +
 = 440.1.  
3-(2-Amino-4-oxo-3-(4-(trifluoromethyl)phenyl)-3,4-dihydroquinazolin-6-yl)-N,N-
dimethylbenzamide (5.11) 
Obtained from 4 (212.6 mg, 0.49 mmol, 
1.0 Eq) using 3-(N,N-dimethylamino 
carbonyl)phenylboronic acid (142.7 
mg, 0.74 mmol, 1.5 Eq), as a pale yellow 
solid (100.1 mg, 45%); m.p 286.0 – 
288.9 °C; Rf (5% MeOH in EtOAc) 0.34; 
1H NMR (400 MHz, DMSO-d6) δ 8.16 (d, 
J = 2.3 Hz, 1H, H1), 8.00 (dd, J = 8.6, 2.4 Hz, 1H, H2), 7.95 (d, J = 8.3 Hz, 2H, H5), 7.77 (ddd, 
J = 7.9, 1.9, 1.1 Hz, 1H, H10), 7.68 (t, J = 2.0 Hz, 1H, H7), 7.66 (d, J = 8.2 Hz, 2H, H4), 7.54 (t, 
J = 7.7 Hz, 1H, H9), 7.37 (dt, J = 7.6, 1.2 Hz, 1H, H8), 7.36 (d, J = 8.6 Hz, 1H, H3), 6.54 (s, 2H, 
H6), 3.01 (s, 3H, H11), 2.97 (s, 3H, H11’); 13C NMR (101 MHz, DMSO-d6) δ 170.42, 162.27, 
151.96, 150.44, 139.85, 139.74, 137.83, 133.59, 133.00, 130.66 (2C), 130.11 (q, J = 32.0 
Hz, 1C, C-CF3), 129.53, 127.54 (3C), 126.04, 125.27, 125.08, 124.56 (q, J = 272.48 Hz, 1C, 




6.2.3. GENERAL PROCEDURE FOR THE SYNTHESIS OF INTERMEDIATES 6.1 – 6.3 
The appropriate methyl 2-aminobromobenzoate (1.0 Eq) was dissolved in acetonitrile 
(10 mL) and the yellow solution was treated with ethoxycarbonyl isothiocyanate        
(1.2 Eq). After stirring for 10 minutes at room temperature, the precipitate that formed 
was filtered, the resulting mother liquor was concentrated and solids refiltered to afford 




























Methyl 5-bromo-2-(3-(ethoxycarbonyl)thioureido)benzoate (6.1) 
Obtained from methyl 2-amino-5-bromobenzoate (3.58 
g, 15.57 mmol, 1.0 Eq) to afford 6.1 as a pale yellow solid 
(5.09 g, 90%); m.p 155.4 – 159.7 °C; Rf (EtOAc:Hex, 3:7) 
0.51; 1H NMR (400 MHz, Chloroform-d) δ 12.61 (s, 1H, 
H4), 8.47 (d, J = 8.9 Hz, 1H, H3), 8.18 (s, 1H, H5), 8.16 (d, J 
= 2.4 Hz, 1H, H1), 7.68 (dd, J = 8.8, 2.5 Hz, 1H, H2), 4.35 (q, 
J = 7.1 Hz, 2H, H6), 3.97 (s, 3H, H8), 1.37 (t, J = 7.1 Hz, 3H, 
H7); 13C NMR (101 MHz, Chloroform-d) δ 178.10, 165.46, 
151.67, 137.95, 135.35, 133.42, 127.86, 123.54, 118.74, 
63.07, 52.81, 14.21; HPLC-MS (APCI/ESI): Purity >99%, tR = 4.202 min, m/z [M+H]
+ 
= 
360.9, 362.9 (1:1). 
Methyl 4-bromo-2-(3-(ethoxycarbonyl)thioureido)benzoate (6.2) 
Obtained from methyl 2-amino-4-bromobenzoate 
(612.3 mg, 2.66 mmol, 1.0 Eq) to afford 6.2 as a white 
solid (698 mg, 73%); m.p. 143.3 – 147.1°C; Rf (5:5 
EtOAc:Hexane) 0.57; 1H NMR (400 MHz, DMSO-d6) δ 
12.24 (s, 1H, H4), 11.37 (s, 1H, H5), 8.39 (d, J = 2.1 Hz, 1H, 
H3), 7.85 (d, J = 8.5 Hz, 1H, H1), 7.58 (dd, J = 8.5, 2.0 Hz, 
1H, H2), 4.25 (q, J = 7.1 Hz, 2H, H6), 3.84 (s, 3H, H8), 1.28 
(t, J = 7.1 Hz, 3H, 7); 13C NMR (101 MHz, DMSO-d6) δ 
179.91, 165.66, 153.55, 139.99, 132.41, 130.49, 129.39, 125.78, 123.06, 62.59, 53.06, 
14.61; HPLC-MS (APCI/ESI): Purity 95%, tR = 4.823 min, m/z [M+H]
+ 









































Methyl 2-bromo-6-(3-(ethoxycarbonyl)thioureido)benzoate (6.3) 
Obtained from methyl 2-amino-6-bromobenzoate (0.35 
mL, 2.40 mmol, 1.0 Eq) to afford 6.3 as a light yellow solid 
(303.6 mg, 35%); m.p. 117.2 – 119.9°C; Rf (3:7 
EtOAc:Hexane) 0.38; 1H NMR (300 MHz, DMSO-d6) δ 11.54 
(s, 1H, H4), 11.48 (s, 1H, H5), 7.84 (dd, J = 8.1, 1.0 Hz, 1H, 
H3), 7.65 (dd, J = 8.1, 1.0 Hz, 1H, H1), 7.47 (t, J = 8.1 Hz, 1H, 
H2), 4.23 (q, J = 7.1 Hz, 2H, H6), 3.86 (s, 3H, H8), 1.27 (t, J = 
7.1 Hz, 3H, H7); 13C NMR (101 MHz, DMSO-d6) δ 180.63, 
165.95, 154.23, 137.06, 131.93, 131.64, 131.42, 128.13, 118.68, 62.92, 53.45, 14.50; 
HPLC-MS (APCI/ESI): Purity >99%, tR = 4.453 min, m/z [M+H]
+ 
= 360.9, 362.9 (1:1).  
6.2.4. GENERAL PROCEDURE FOR THE SYNTHESIS OF COMPOUNDS 7.1 – 7.9  
Compounds 6.1 – 6.3 (1.0 Eq) were dissolved in DCM or DMF and the relative primary 
cyclic amine (1.5 Eq) and EDCI (2.0 Eq) were successively added to the solution. The 
solution was allowed to stir at room temperature (21.3–24.9°C) until completion, as per 
TLC and LCMS monitoring (18-22 hours). Once complete, DMF solutions were diluted 
with EtOAc and washed with 5% LiCl (5x), thereafter all solutions were washed with 1% 
of 1M HCl (x2), water, brine (x3) and dried over magnesium sulphate. The solvent was 
concentrated under reduced pressure to furnish compounds 7.1 – 7.5. 
Ethyl (6-bromo-3-(2-hydroxyphenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)carbamate (7.1)  
Obtained from 6.1 (310.6 mg, 0.86 mmol, 1.0 Eq) 
using 2-aminophenol (140.8 mg, 1.29 mmol, 1.5 Eq), 
to give a light brown solid (154.6 mg, 38%); m.p. 
186.1 – 190.1°C; Rf (5% MeOH in DCM) 0.48; 1H 
NMR (400 MHz, DMSO-d6) δ 12.35 (s, 1H, H4), 9.62 
(s, 1H, H11), 8.10 (d, J = 2.3 Hz, 1H, H1), 7.97 (dd, J = 
8.8, 2.4 Hz, 1H, H2), 7.72 (d, J = 8.8 Hz, 1H, H3), 7.27 
(ddd, J = 8.1, 7.3, 1.7 Hz, 1H, H9), 7.16 (dd, J = 7.8, 1.7 
Hz, 1H, H7), 6.95 (dd, J = 8.2, 1.3 Hz, 1H, H10), 6.89 
(td, J = 7.6, 1.4 Hz, 1H, H8), 3.99 (q, J = 7.1 Hz, 2H, H5), 1.13 (t, J = 7.1 Hz, 3H, H6); 13C NMR 







































130.24, 129.41, 126.78, 123.37, 119.47, 116.98, 113.07, 61.36, 14.71; HPLC-MS 
(APCI/ESI): Purity 95%, tR = 4.258 min, m/z [M+H]
+ 
= 404.0, 406.0 (1:1).  
Ethyl (6-bromo-3-(3-hydroxyphenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)carbamate (7.2)  
Obtained from 6.1 (310.6 mg, 0.86 mmol, 1.0 Eq) 
using 3-aminophenol (140.8 mg, 1.29 mmol, 1.5 Eq), 
as a white solid (108.7 mg, 31%); m.p.  350.9 – 
356.9°C; Rf (5% MeOH in DCM) 0.48; 1H NMR (400 
MHz, DMSO-d6) δ 12.11 (s, 1H, H4), 9.67 (s, 1H, H11), 
8.10 (d, J = 2.3 Hz, 1H, H1), 7.96 (dd, J = 8.7, 2.4 Hz, 1H, 
H2), 7.70 (d, J = 8.7 Hz, 1H, H3), 7.28 (t, J = 8.3 Hz, 1H, 
H8), 6.85 (ddd, J = 8.2, 2.2, 1.2 Hz, 1H, H7), 6.73 – 6.72 
(m, 1H, H9), 6.71 – 6.70 (m, 1H, H10), 3.99 (q, J = 7.1 
Hz, 2H, H5), 1.13 (t, J = 7.1 Hz, 3H, H6); 13C NMR (101 MHz, DMSO-d6) δ 162.72, 160.02, 
158.23, 153.85, 138.42, 137.49, 130.04, 129.47, 120.09, 119.70, 118.13, 116.41 (2C), 
116.02, 115.88, 61.50, 14.85; HPLC-MS (APCI/ESI): Purity 95%, tR = 4.273 min, m/z 
[M+H]
+ 
= 404.0, 406.0 (1:1).  
Ethyl(6-bromo-3-((1r,4r)-4-hydroxycyclohexyl)-4-oxo-3,4-dihydroquinazolin-2-yl)carbamate 
(7.3) 
 Obtained from 6.1 (307.3 mg, 0.85 mmol, 1.0 Eq) 
using trans-4-aminocyclohexanol (146.9 mg, 1.28 
mmol, 1.5 Eq) to afford a white solid (164.3 mg, 
47%); m.p.  310.0 – 317.7°C; Rf (5% MeOH in DCM) 
0.41; 1H NMR (400 MHz, DMSO-d6) δ 12.28 (s, 1H, 
H4), 8.05 (d, J = 2.3 Hz, 1H, H1), 7.88 (dd, J = 8.7, 2.3 
Hz, 1H, H2), 7.60 (d, J = 8.7 Hz, 1H, H3), 5.00 (m, 1H, 
H7), 4.58 (d, J = 4.6 Hz, 1H, H11), 4.16 (q, J = 7.1 Hz, 
2H, H5), 3.44 (td, J = 11.0, 4.5 Hz, 1H, H10), 2.54 (q, J = 12.4 Hz, 2H, H8ax), 1.93 (d, J = 13.0 
Hz, 2H, H9eq), 1.61 (d, J = 12.3 Hz, 2H, H8eq), 1.28 (t, J = 7.1 Hz, 4H, H6), 1.24 – 1.15 (m, 1H, 
H9ax); 13C NMR (101 MHz, DMSO-d6) δ 162.27, 160.36, 152.99, 138.07, 137.05, 129.28, 
120.18, 118.41, 116.71, 68.69, 61.55, 55.34, 35.51 (2C), 26.02 (2C), 14.86; HPLC-MS 
(APCI/ESI): Purity >99%, tR = 4.802 min, m/z [M+H]
+ 











































Ethyl (3-(4-aminophenyl)-6-bromo-4-oxo-3,4-dihydroquinazolin-2-yl)carbamate (7.4) 
Obtained from 6.1 (246.1 mg, 0.68 mmol, 1.0 Eq.) 
using p-phenylenediamine (81.0 mg, 0.75 mmol, 
1.1 Eq), as a white solid (222.7 mg, 81%); m.p.  
331.2 – 339.4°C; Rf (100% EtOAc) 0.57; 1H NMR 
(400 MHz, DMSO-d6) δ 12.15 (s, 1H, H4), 8.10 (d, J = 
2.3 Hz, 1H, H1), 7.95 (dd, J = 8.7, 2.4 Hz, 1H, H2), 
7.65 (d, J = 8.7 Hz, 1H, H3), 6.89 (d, J = 8.6 Hz, 2H, 
H7), 6.62 (d, J = 8.6 Hz, 2H, H8), 5.29 (s, 2H, H9), 3.99 
(q, J = 7.1 Hz, 2H, H5), 1.14 (t, J = 7.1 Hz, 3H, H6); 13C 
NMR (101 MHz, DMSO-d6) δ 173.85, 161.96, 161.42, 149.30, 147.10, 138.35 (2C), 129.36 
(2C), 124.11, 124.01, 121.45 114.08 (2C), 113.28, 61.37, 14.72; HPLC-MS (APCI/ESI): 
Purity 95%, tR = 4.100 min, m/z [M+H]
+ 




Obtained from 6.1 (546.7 mg, 1.51 mmol, 1.0 Eq) 
using (1-methyl-4-piperidinyl)methanamine 
(0.32mL, 2.27 mmol, 1.5 Eq), as a white solid 
(633.8 mg, 98%); m.p. 174.2 – 180.4°C; Rf (2 x 10% 
MeOH in DCM) 0.45; 1H NMR (400 MHz, DMSO-d6) 
δ 7.95 (d, J = 2.4 Hz, 1H, H1), 7.67 (dd, J = 8.7, 2.5 
Hz, 1H, H2), 7.12 (d, J = 8.8 Hz, 1H, H3), 4.32 (s, 1H, 
H4), 4.15 (q, J = 7.1 Hz, 2H, H10), 3.93 (d, J = 7.5 Hz, 
2H, H5), 2.73 (d, J = 11.9 Hz, 2H, H8eq), 2.14 (s, 3H, H9), 1.72 – 1.82 (m, 2H, H8ax), 1.74 – 
1.65 (m, 1H, H6), 1.51 (m, 2H, H7eq), 1.36 – 1.23 (m, 2H, H7ax), 1.26 (t, J = 7.1 Hz, 3H, H11); 
13C NMR (101 MHz, DMSO-d6) δ 152.89, 138.07, 137.17, 128.96, 126.66, 117.97, 113.07, 
55.42 (2C), 46.49, 46.20, 45.54, 40.47, 33.99, 29.52 (2C), 19.02, 14.93; HPLC-MS 
(APCI/ESI): Purity = >99%, tR = 3.020 min, m/z [M+H]
+ 





























Obtained from 6.1 (4.9402 g, 13.68 mmol, 1.0 Eq) 
using 4-(trifluoromethyl)aniline (3.31 g, 20.52 
mmol, 1.5 Eq), as a pale yellow solid (4.31 g, 69%); 
m.p 282.7 – 290.5 °C; Rf (3:7 EtOAc:Hexane) 0.28; 1H 
NMR (400 MHz, Chloroform-d) δ 13.00 (s, 1H, H4), 
8.33 (d, J = 2.3 Hz, 1H, H1), 7.84 (dd, J = 8.7, 2.3 Hz, 
1H, H2), 7.81 (d, J = 8.3 Hz, 2H, H6), 7.40 (d, J = 8.0 
Hz, 2H, H5), 7.18 (d, J = 8.4 Hz, 1H, H3), 4.12 (q, J = 
7.1 Hz, 2H, H7), 1.26 (t, J = 7.1 Hz, 3H, H8); 13C NMR (151 MHz, DMSO-d6) δ 162.42, 
160.06, 153.63, 140.54, 138.64, 137.71, 130.66, 130.10 (q, J = 32.00 Hz, 1C, C-CF3), 
129.48 (2C), 126.61 (2C), 122.37 (q, J = 161.28 Hz, 1C, CF3), 120.23, 118.09, 116.59, 





Ethyl (6-bromo-3-(4-hydroxyphenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)carbamate (7.7) 
Obtained from 6.1 (1.51 g, 4.17 mmol, 1.0 Eq) using 4-
aminophenol (682.2 mg, 6.25 mmol, 1.5 Eq), as a 
white solid (1.038 g, 62%); m.p. 317.8 – 322.4 °C; Rf 
(5:5 EtOAc:Hexane) 0.30; 1H NMR (400 MHz, DMSO-
d6) δ 12.12 (s, 1H, H4), 9.67 (s, 1H, H9), 8.10 (d, J = 2.3 
Hz, 1H, H1), 7.96 (dd, J = 8.7, 2.4 Hz, 1H, H2), 7.68 (d, J 
= 8.6 Hz, 1H, H3), 7.07 (d, J = 8.7 Hz, 2H, H7), 6.84 (d, J 
= 8.8 Hz, 2H, H8), 3.98 (q, J = 7.1 Hz, 2H, H5), 1.12 (t, J = 
7.1 Hz, 3H, H6); 13C NMR (151 MHz, DMSO-d6) δ 162.74, 160.96, 160.04, 157.81, 154.08, 
145.83, 138.36, 130.15 (2C), 129.45, 127.34, 120.06, 118.08, 115.91 (2C), 61.48, 14.82; 
HPLC-MS (APCI/ESI): Purity >99%, tR = 4.212  min, m/z [M+H]
+ 
























Ethyl (7-bromo-3-(4-hydroxyphenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)carbamate (7.8) 
Obtained from 6.2 (457.2 mg, 1.27 mmol, 1.0 Eq) 
using 4-aminophenol (207.2 mg, 1.90 mmol, 1.5 Eq) 
to give a white solid (210.4 mg, 41%); m.p. 193.4 – 
200.1°C; Rf (5:5 EtOAc:Hexane) 0.43; 1H NMR (300 
MHz, DMSO-d6) δ 12.26 (s, 1H, H4), 9.63 (s, 1H, H9), 
8.01 (s, 1H, H3), 7.93 (d, J = 8.5 Hz, 1H, H1), 7.54 (d, J = 
7.4 Hz, 1H, H2), 7.05 (d, J = 8.7 Hz, 2H, H7), 6.83 (d, J = 
8.7 Hz, 2H, H8), 3.99 (q, J = 7.1 Hz, 2H, H5), 1.13 (t, J = 
7.1 Hz, 3H, H6); 13C NMR (101 MHz, DMSO-d6) δ 161.10, 157.61, 153.08, 149.82, 137.95, 
130.15 (2C), 129.34, 129.52, 127.55, 125.80, 120.25, 115.85 (2C), 113.02, 61.37, 14.69; 
HPLC-MS (APCI/ESI): Purity 98%, tR = 4.298 min, m/z [M+H]
+ 
= 404.0, 406.0 (1:1). 
Ethyl (5-bromo-3-(4-hydroxyphenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)carbamate (7.9) 
Obtained from 6.3 (248.0 mg, 0.69 mmol, 1.0 Eq) 
using 4-aminophenol (112.4 mg, 1.03 mmol, 1.5 Eq), 
as a white solid (142 g, 51%); m.p. 314.8 – 319.9°C; Rf 
(7:3 EtOAc:Hexane) 0.56; 1H NMR (400 MHz, DMSO-
d6) δ 11.52 (s, 1H, H4), 9.70 (s, 1H, H9), 7.83 – 7.49 (m, 
3H, H1, H2, H3), 7.06 (d, J = 8.7 Hz, 2H, H7), 6.85 (d, J = 
8.8 Hz, 2H, H8), 3.98 (q, J = 7.1 Hz, 2H, H5), 1.12 (t, J = 
7.1 Hz, 3H, H6); 13C NMR (101 MHz, DMSO-d6) δ 
162.94, 160.82, 159.89, 157.76, 137.20, 134.61, 132.25, 131.87, 130.18 (2C), 127.53, 
121.93, 117.92, 115.85 (2C), 61.34, 14.72; HPLC-MS (APCI/ESI): Purity >99%, tR = 4.021 
min, m/z [M+H]
+ 
= 404.0, 406.0. 
6.2.5. GENERAL PROCEDURE FOR THE SYNTHESIS OF COMPOUNDS 8.1 – 8.4  
Compound 6.1 (1.0 Eq) was dissolved in DMF (3–6 mL) and the relevant primary amine 
(1.5 Eq) and EDCI (2.0 Eq) were successively added to the solution. After stirring at 
room temperature (24 – 26°C) for 5 hours, the solution was heated under pressure at 
100°C for 18 - 22 hours. The solution was cooled to room temperature, diluted with 
EtOAC and washed with 5% LiCl (x5), water and brine. The organic layer was dried over 








































by stirring in Et2O to afford the cyclized and deprotected penultimate compounds 8.1 – 
8.4. 
2-Amino-6-bromo-3-((1r,4r)-4-methoxycyclohexyl)quinazolin-4(3H)-one (8.1) 
Obtained using 4-methoxycyclohexanamine 
(0.31mL, 2.27 mmol, 1.5 Eq.) as a light brown solid 
(350 mg, 55%); m.p. 241.1 – 243.3°C; Rf (2 x 5% 
MeOH in DCM) 0.3; 1H NMR (400 MHz, DMSO-d6) δ 
7.92 (d, J = 2.4 Hz, 1H, H1), 7.65 (dd, J = 8.7, 2.5 Hz, 
1H, H2), 7.09 (d, J = 8.6 Hz, 1H, H3), 7.09 (s, 2H, H4), 
4.20 (m, 1H, H5), 3.26 (s, 3H, H9), 3.26 – 3.13 (m, 
1H, H8), 2.59 (qd, J = 12.9, 3.4 Hz, 2H, H6ax), 2.06 (d, J = 12.4 Hz, 2H, H7eq), 1.66 (d, J = 12.4 
Hz, 2H, H6eq), 1.31 (qd, J = 13.3, 3.7 Hz, 2H, H7ax); 13C NMR (101 MHz, DMSO-d6) δ 161.92, 
153.15, 149.02, 137.08, 128.58, 126.36, 119.38, 113.11, 78.10, 56.40, 55.64, 31.25 (2C), 





Obtained using 4-(2-aminoethyl)morpholine (0.29 
mL, 2.18 mmol, 1.5 Eq) as a light orange solid 
(354.9 mg, 69%); m.p. 216.5 – 221.0 °C; Rf (5% 
MeOH in EtOAc) 0.18; 1H NMR (400 MHz, DMSO-d6) 
δ 7.96 (d, J = 2.4 Hz, 1H, H1), 7.67 (dd, J = 8.8, 2.5 
Hz, 1H, H2), 7.26 (s, 2H, H4), 7.13 (d, J = 8.8 Hz, 1H, 
H3), 4.15 (t, J = 6.2 Hz, 2H, H5), 3.55 (t, J = 4.6 Hz, 
4H, H8), 2.58 (t, J = 6.2 Hz, 2H, H6), 2.49 (t, J = 4.8 
Hz, 4H, H7); 13C NMR (101 MHz, DMSO-d6) δ 
161.31, 153.24, 149.27, 137.18, 128.84, 126.74, 118.21, 113.22, 66.69 (2C), 56.29, 53.88 
(2C), 40.06; HPLC-MS (APCI/ESI): Purity 86%, tR = 3.533 min, m/z [M+H]
+ 
= 355.1, 

























hydroxy propane (395.6 mg, 2.51 mmol, 1.5 Eq) as 
a light brown solid (250.9 mg, 40 %); m.p. 248.6 – 
255.7°C; Rf (5% MeOH in DCM) 0.25; 1H NMR (400 
MHz, DMSO-d6) δ 7.92 (d, J = 2.4 Hz, 1H, H1), 7.64 
(dd, J = 8.7, 2.5 Hz, 1H, H2), 7.09 (d, J = 8.8 Hz, 1H, 
H3), 7.04 (s, 2H, H4), 4.27 – 4.07 (m, 1H, H5), 2.60 – 
2.44 (m, 2H, H6ax), 1.87 (d, J = 12.0 Hz, 2H, H7eq), 
1.67 (d, J = 10.0 Hz, 2H, H6eq), 1.35 – 1.25 (m, 2H, H8), 1.25 – 1.13 (m, 1H, H7ax), 1.07 (s, 
6H, H9); 13C NMR (101 MHz, DMSO-d6) δ 161.92, 153.25, 149.04, 137.01, 128.61, 126.35, 
119.46, 113.05, 71.00, 55.35, 47.89, 28.11 (2C), 27.49 (2C), 26.95 (2C); HPLC-MS 
(APCI/ESI): Purity 96%, tR = 4.826 min, m/z [M+H]
+ 
= 380.1, 382.1 (1:1). 
2-Amino-6-bromo-3-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)quinazolin-4(3H)-one (8.4) 
4-aminoterahydro-2H-thiopyran-1,1-dioxide, HCl (553 
mg, 2.98 mmol, 1.5 Eq) was used with the addition of 
Et3N (0.5 mL), since the amine reagent is a salt, to obtain 
a light brown solid (313 mg, 42%); m.p. 237.2 – 243.4°C; 
Rf (5% MeOH in DCM) 0.25; 1H NMR (400 MHz, DMSO-
d6) δ 7.94 (d, J = 2.5 Hz, 1H, H1), 7.67 (dd, J = 8.7, 2.5 Hz, 
1H, H2), 7.18 (s, 2H, H4), 7.11 (d, J = 8.7 Hz, 1H, H3), 4.39 
(m, 1H, H5), 3.27 – 3.11 (m, 6H, H7, H6ax), 2.01 (d, J = 13.5 Hz, 2H, H6eq); 13C NMR (101 
MHz, DMSO-d6) δ 161.96, 152.79, 149.06, 137.31, 128.56, 126.47, 119.37, 113.34, 54.21, 
50.89 (2C), 26.32 (2C); HPLC-MS (APCI/ESI): Purity 96%, tR = 3.729 min, m/z [M+H]
+ 
= 
372.0, 374.0 (1:1).  
6.2.6. GENERAL PROCEDURE FOR THE SYNTHESIS OF COMPOUNDS 8.5 – 8.7  
Compounds 7.1–7.2 (1.0 Eq) were dissolved in TFA (20 Eq) and microwaved at 100°C 
for 20 minutes. Once complete, the reaction was diluted with methanol and 
concentrated in vacuo. The crude residue was taken up in ethyl acetate, neutralized with 
saturated sodium bicarbonate and the aqueous layer was extracted with ethyl acetate 






































aminoquinazolinone intermediates 8.1 – 8.3. 
2-Amino-6-bromo-3-((1-methylpiperidin-4-yl)methyl)quinazolin-4(3H)-one (8.5) 
Obtained using 7.2 (573.8 mg, 1.36 mmol, 1.0 Eq) 
as an white solid (454.9 mg, 96%); m.p. 224.2 – 
228.4°C; Rf (1 x 10% MeOH in DCM) 0.05; 1H NMR 
(400 MHz, DMSO-d6) δ 7.95 (d, J = 2.4 Hz, 1H, H1), 
7.67 (dd, J = 8.8, 2.4 Hz, 1H, H2), 7.12 (d, J = 8.9 Hz, 
1H, H3), 7.10 (s, 2H, H4), 3.93 (d, J = 7.5 Hz, 2H, H5), 
2.72 (d, J = 11.7 Hz, 2H, H8eq), 2.11 (s, 3H, H9), 1.73 
(td, J = 11.4, 2.4 Hz, 2H, H8ax), 1.72 – 1.65 (m, 1H, H6), 1.48 (d, J = 12.4 Hz, 2H, H7eq), 1.28 
(qd, J = 12.12, 3.8 Hz, 2H, H7ax); 13C NMR (101 MHz, DMSO-d6) δ 161.51, 152.89, 149.32, 
137.18, 128.96, 126.67, 117.96, 113.09, 55.47 (2C), 46.58, 46.23, 34.04, 29.57 (2C); 
HPLC-MS (APCI/ESI): Purity = >99%, tR = 1.385 min, m/z [M+H]
+ 
= 351.1, 353.1 (1:1). 
2-Amino-6-bromo-3-(4-(trifluoromethyl)phenyl)quinazolin-4(3H)-one (8.6) 
Obtained using 7.1 (4.17 g, 9.14 mmol, 1.0 Eq) as an 
off-white solid (2.90 g, 83%); m.p 302.4 –306.6 °C; Rf 
(3:7 EtOAc:Hexane) 0.08; 1H NMR (400 MHz, DMSO-
d6) δ 7.93 (d, J = 2.4 Hz, 1H, H1), 7.91 (d, J = 8.0 Hz, 
2H, H6), 7.71 (dd, J = 8.8, 2.5 Hz, 1H, H2), 7.61 (d, J = 
7.8 Hz, 2H, H5), 7.18 (d, J = 8.8 Hz, 1H, H3), 6.57 (s, 
2H, H4); 13C NMR (101 MHz, DMSO-d6) δ 161.26, 
152.17, 149.89, 139.48, 137.63, 130.59 (2C), 130.19 (q, J = 32.0 Hz, 1C, C-CF3), 128.81, 
127.59 (2C), 126.89, 122.37 (q, J = 161.3 Hz, 1C, CF3) 118.66, 113.29; HPLC-MS 
(APCI/ESI): Purity = 96%, tR = 4.080 min, m/z [M+H]
+ 








Obtained from 7.4 (980.8 mg, 2.43 mmol, 1.0 Eq.), as a 
light pink solid (426.4 mg, 53%); m.p. 310.1 – 318.2 
°C; Rf (100% EtOAc) 0.44; 1H NMR (400 MHz, DMSO-
d6) δ 9.79 (s, 1H, H7), 7.94 (d, J = 2.5 Hz, 1H, H1), 7.71 
(dd, J = 8.8, 2.5 Hz, 1H, H2), 7.19 (d, J = 8.7 Hz, 1H, H3), 
7.13 (d, J = 8.7 Hz, 2H, H5), 6.92 (d, J = 8.7 Hz, 2H, H6), 
6.38 (s, 2H, H4); 13C NMR (101 MHz, DMSO-d6) δ 
161.46, 158.45, 153.13, 149.71, 137.36, 130.12 (2C), 128.85, 126.81, 126.39, 118.87, 
117.01 (2C), 113.14; HPLC-MS (APCI/ESI): Purity >99%, tR = 3.843 min, m/z [M+H]
+ 
= 
332.0, 334.0 (1:1).  
6.2.7. GENERAL PROCEDURE SUZUKI MIYAURA COUPLING IN THE SYNTHESIS OF THE 
TARGET COMPOUNDS 9.1 – 9.6  
Compounds 8.1 – 8.7 (1.0 Eq) and the appropriate arylboronic acid (1.5 Eq.) were 
dissolved in 1,4-dioxane or DMF (2 – 4 mL) and the solution was purged with nitrogen. 
PdCl2(PPh3)2 (0.1 Eq) was added to the solution followed by the addition of potassium 
carbonate (3.0 Eq) dissolved in water (0.05 Eq). The reaction was heated at 80°C until 
TLC monitoring showed completion (1-3 hours), allowed to cool to room temperature 
and diluted with EtOAc to be filtered through Celite. The organic phase was washed with 
water and brine, dried over magnesium sulphate and concentrated under reduced 
pressure. The resulting crude residue was purified by silica-gel chromatography using 
the relevant solvent system, combined pure fractions were concentrated in vacuo, 
triturated with Et2O, filtered and dried under vacuum to give the relevant target 

































Obtained from 8.4 (304.5 mg, 0.86 
mmol, 1.0 Eq), using 3-
methylsulfinylphenyl boronic acid 
(256.8 mg, 1.40 mmol, 1.6 Eq), as a 
brown solid (54 mg, 11%); m.p 221.3 – 
223.6 °C; Rf (1:9, MeOH:DCM) 0.41; 1H 
NMR (400 MHz, DMSO-d6) δ 8.18 (d, J = 
2.3, 1H, H1), 7.96 (t, J = 2.1 Hz, 1H, H10), 7.94 (dd, J = 8.5, 2.3 Hz, 1H, H2), 7.84 (dt, J = 6.8, 
2.0 Hz, 1H, H11), 7.69 – 7.63 (m, 2H, H12, H13), 7.27 (d, J = 8.6 Hz, 1H, H3), 7.06 (s, 2H, H4), 
4.24 (m, 1H, H5), 3.27 (s, 3H, H9), 3.26 – 3.15 (m, 1H, H8), 2.82 (s, 3H, H14), 2.65 (qd, J = 
13.6, 3.0 Hz, 2H, H6ax), 2.07 (d, J = 6.6 Hz, 2H, H7eq), 1.69 (d, J = 11.4 Hz, 2H, H6eq), 1.34 
(qd, J = 13.1, 3.7 Hz, 2H, H7ax); 13C NMR (101 MHz, DMSO-d6) δ 163.01, 153.10, 149.83, 
147.80, 140.98, 133.05, 132.32, 130.40, 128.79, 124.75, 124.54, 122.49, 121.43, 118.14, 
78.17, 56.36, 55.64, 43.73, 31.31 (2C), 26.20 (2C); HPLC-MS (APCI/ESI): Purity = 96%, tR 




Obtained from 8.5 (224.5 mg, 0.64 mmol, 
1.0 Eq) using 3-methylsulfinylphenyl 
boronic acid (175.4 mg, 0.95 mmol, 1.5 
Eq) as an off-white solid (45 mg, 17 %); 
m.p. 214.2 – 217.2°C; Rf (3% MeOH in 
DCM) 0.1; 1H NMR (400 MHz, DMSO-d6) 
δ 8.23 (d, J = 2.4 Hz, 1H, H1), 7.97 (t, J = 
2.1 Hz, 1H, H9), 7.96 (dd, J = 8.6, 2.3 Hz, 
1H, H2), 7.85 (dt, J = 6.7, 2.0 Hz, 1H, H10), 
7.70 – 7.64 (m, 2H, H11, H12), 7.31 (d, J = 8.6 Hz, 1H, H3), 7.11 (s, 2H, H4), 4.20 (t, J = 6.2 
Hz, 2H, H5), 3.64 – 3.51 (m, 4H, H8), 2.82 (s, 3H, H13), 2.64 (t, J = 6.2 Hz, 2H, H6), 2.54 – 
2.52 (m, 4H, H7); 13C NMR (101 MHz, DMSO-d6) δ 162.37, 153.13, 150.04, 147.84, 
140.87, 133.17, 132.43, 130.42, 128.82, 125.12, 124.79, 122.55, 121.44, 116.94, 66.57 
(2C), 56.34, 53.82 (2C), 43.76, 39.48; HPLC-MS (APCI/ESI): Purity 98%, tR = 3.126 min, 
m/z [M+H]
+ 




























Obtained from 8.6 (220.5 mg, 0.58 
mmol, 1.0 Eq) using 3-
methylsulfinylphenyl boronic acid 
(160.0 mg, 0.87 mmol, 1.5 Eq) as an off-
white solid (55.1 mg, 22%); m.p. 232.0 
– 237.2°C; Rf (5% MeOH in DCM with 
1% Et3N) 0.23; 1H NMR (400 MHz, 
DMSO-d6) δ 8.18 (d, J = 2.3 Hz, 1H, H1), 
7.96 (t, J = 1.8 Hz, 1H, H10), 7.94 (dd, J = 8.6, 2.3 Hz, 1H, H2), 7.85 (dt, J = 6.8, 2.0 Hz, 1H, 
H11), 7.67 (t, J = 7.7 Hz, 1H, H12), 7.68 – 7.63 (m, 1H, H13), 7.26 (d, J = 8.6 Hz, 1H, H3), 7.01 
(s, 2H, H4), 4.21 (m, 1H, H5), 2.82 (s, 3H, H14), 2.59 (q, J = 12.0 Hz, 2H, H6ax), 1.89 (d, J = 
11.8 Hz, 2H, H7eq), 1.71 (d, J = 12.2 Hz, 2H, H6eq), 1.35 – 1.26 (m, 1H, H8), 1.26 – 1.20 (m, 
2H, H7ax), 1.08 (s, 6H, H9); 13C NMR (101 MHz, DMSO-d6) δ 163.00, 153.22, 149.87, 
147.84, 141.01, 132.97, 132.24, 130.39, 128.78, 124.73, 124.57, 122.46, 121.43, 118.23, 
71.03, 57.30, 47.96, 43.75, 28.27 (2C), 27.51 (2C), 27.03 (2C); HPLC-MS (APCI/ESI): 
Purity 98%, tR = 4.266 min, m/z [M+H]
+ 
= 440.2, 442.2 (1:1).  
2-Amino-3-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-6-(3-(methylsulfinyl)phenyl) 
quinazolin-4(3H)-one (9.4) 
Obtained from 8.7 (274.4 mg, 0.75 mmol, 
1.0 Eq) using 3-methylsulfinylphenyl 
boronic acid (203.5 mg, 1.11 mmol, 1.5 Eq) 
as a white solid (55.2 mg, 17%); m.p. 328.1 
– 333.2°C; Rf (5% MeOH in DCM) 0.2; 1H 
NMR (400 MHz, DMSO-d6) δ 8.20 (d, J = 2.3 
Hz, 1H, H1), 7.97 (t, J = 1.8 Hz, 1H, H8), 7.97 
(dd, J = 8.6, 2.4 Hz, 1H, H2), 7.86 (dt, J = 6.7, 2.1 Hz, 1H, H9), 7.72 – 7.63 (m, 1H, H10), 7.66 
(m, 1H, H11), 7.28 (d, J = 8.6 Hz, 1H, H3), 7.15 (s, 2H, H4), 4.41 (m, 1H, H5), 3.27 – 3.14 (m, 
6H, H7, H6ax), 2.82 (s, 3H, H12), 2.04 (d, J = 10.1 Hz, 2H, H6eq); 13C NMR (101 MHz, DMSO-
d6) δ 163.03, 152.72, 149.85, 147.88, 140.87, 133.27, 132.53, 130.42, 128.80, 124.86, 
124.51, 122.55, 121.47, 118.13, 54.19, 50.96 (2C), 43.75, 26.45 (2C); HPLC-MS 
(APCI/ESI): Purity 98 %, tR = 3.313 min, m/z [M+H]
+ 

















































one  (9.5) 
Obtained from 8.2 (171.4 mg, 0.49 
mmol, 1.0 Eq), using 3-
methylsulfinylphenyl boronic acid 
(134.7 mg, 0.73 mmol, 1.5 Eq), as an 
off-white solid (20.4 mg, 20%); m.p. 
235.7 – 237.8°C; Rf (2:7.9:0.1, 
MeOH:DCM:Et3N) 0.26; 1H NMR (400 
MHz, DMSO-d6) δ 8.22 (d, J = 2.3 Hz, 1H, H1), 7.97 (m, 1H, H10), 7.96 (dd, J = 8.6, 2.3 Hz, 
1H, H2), 7.86 (d, J = 6.8 Hz, 1H, H11), 7.68 (t, J = 7.4 Hz, 1H, H12), 7.66 (m, 1H, H13), 7.29 (d, 
J = 8.5 Hz, 1H, H3), 7.09 (s, 2H, H4), 3.98 (d, J = 7.5 Hz, 2H, H5), 2.82 (s, 3H, H14), 2.79 (d, J 
= 11.9 Hz, 2H, H8eq), 2.17 (s, 3H, H9), 1.85 (m, 2H, H8ax), 1.78 (m, 1H, H6), 1.54 (d, J = 12.7 
Hz, 2H, H7eq), 1.33 (qd, J = 12.1, 3.8 Hz, 2H, H7ax); 13C NMR (101 MHz, DMSO-d6) δ 162.55, 
152.83, 150.14, 147.80, 140.92, 133.15, 132.31, 130.41, 128.81, 125.07, 124.92, 122.50, 
121.45, 116.71, 55.28 (2C), 46.23, 46.02, 43.76, 33.92, 29.37 (2C); HPLC-MS (APCI/ESI): 
Purity = 98%, tR = 1.987 min, m/z [M+H]
+ 
= 411.1.  
3-(2-Amino-4-oxo-3-(4-(trifluoromethyl)phenyl)-3,4-dihydroquinazolin-6-yl)benzoic acid 
(9.6) 
Obtained from 8.1 (250 mg, 0.65 mmol, 
1.0 Eq), using 3-carboxyphenylboronic 
acid (161.9 mg, 0.98 mmol, 1.5 Eq), as a 
yellow solid (31.6 mg, 11%); m.p. 319.1 – 
323.6°C; Rf (15% MeOH in DCM) 0.41; 1H 
NMR (400 MHz, DMSO-d6) δ 8.21 (t, J = 1.9 
Hz, 1H, H7), 8.17 (d, J = 2.3 Hz, 1H, H1), 
8.01 (dd, J = 8.6, 2.3 Hz, 1H, H2), 7.95 (d, J = 8.4 Hz, 2H, H5), 7.95 – 7.93 (m, 1H, H10), 7.92 
(m, 1H, H8), 7.67 (d, J = 8.2 Hz, 2H, H4), 7.60 (t, J = 7.7 Hz, 1H, H9), 7.38 (d, J = 8.6 Hz, 1H, 
H3), 6.56 (s, 2H, H6); 13C NMR (101 MHz, DMSO-d6) δ 167.88, 162.30, 151.99, 150.48, 
140.03, 139.71, 133.52, 132.84, 132.60, 130.81, 130.65 (2C), 130.12 (q, J = 32.0 Hz, 1C, 
C-CF3), 129.85, 128.41, 127.59, 127.55, 127.24, 125.37, 124.55 (q, J = 272.3 Hz, 1C, CF3), 





























Compound 8.1 (1.03 g, 2.68 mmol, 1.0 Eq) and bis(pinacolato)diboron (1.23 g, 3.49 
mmol, 1.3 Eq) were dissolved in anhydrous 1,4-dioxane (13mL) and flushed with 
nitrogen. PdCl2(dppf)-DCM (219.0 mg, 0.27 mmol, 0.1 Eq) and KOAc (789.7 mg, 8.05 
mmol, 3.0 Eq) were added successively and the reaction was heated at 80°C for 2 hours. 
Once complete, the solution was cooled to room temperature, diluted with EtOAc and 
filtered through Celite. The filtrate was washed with water, brine and dried over 
magnesium sulphate with removal of solvent under reduced pressure. The resulting 
residue was triturated with diethyl ether and filtered to obtain the pinacol ester 10. 
Brown solid (723.8 mg, 63%); m.p 321.2 – 
323.5 °C; Rf (7:3 EtOAc:Hexane) 0.48; 1H 
NMR (400 MHz, DMSO-d6) δ 8.27 (d, J = 1.5 
Hz, 1H, H1), 7.94 (d, J = 7.9 Hz, 2H, H6), 7.84 
(dd, J = 8.3, 1.6 Hz, 1H, H2), 7.64 (d, J = 7.9 
Hz, 2H, H5), 7.22 (d, J = 8.2 Hz, 1H, H3), 6.63 
(s, 2H, H4), 1.31 (s, 12H, H7); 13C NMR (101 
MHz, DMSO-d6) δ 162.23, 153.20, 152.62, 
140.03, 139.64, 134.59, 130.65 (2C), 127.58 (2C), 123.82, 116.56, 84.12 (2C), 60.21, 






Compound 10 (250.9 mg, 0.58 mol, 1.3 Eq) and 2-bromo-4-(methylsulfinyl) toluene 
(111.5 mg, 0.45 mmol, 1.0 Eq) were dissolved in anhydrous 1,4-dioxane (2.7mL) and the 
solution was purged with nitrogen. PdCl2(PPh3)2 (31.4mg, 0.045 mmol, 0.1 Eq) was 
added to the solution followed by the addition of potassium carbonate (185.6 mg, 1.34 
mmol, 3.0 Eq) dissolved in water (0.58 mL). The reaction was heated at 80°C for 3 hours, 
allowed to cool to room temperature and diluted with EtOAc to be filtered through 
Celite. The organic phase was washed with water and brine, dried over magnesium 
sulphate and concentrated under reduced pressure. The resulting crude residue was 
purified by silica gel chromatography (30 – 55% EtOAc/hexane), combined pure 
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fractions were concentrated in vacuo, triturated with Et2O, filtered and dried under 
vacuum to give 11.  
Light brown solid (164.6 mg, 60%); m.p 
278.0 – 282.2°C; Rf (7:3 EtOAc:Hexane) 
0.22; 1H NMR (400 MHz, DMSO-d6) δ 
7.95 (d, J = 8.2 Hz, 2H, H5), 7.88 (d, J = 
2.3 Hz, 1H, H1), 7.83 (dd, J = 8.0, 2.1 Hz, 
1H, H10), 7.75 (d, J = 2.1 Hz, 1H, H7), 7.70 
(dd, J = 8.5, 2.3 Hz, 1H, H2), 7.67 (d, J = 
8.2 Hz, 2H, H4), 7.61 (d, J = 8.0 Hz, 1H, H9), 7.36 (d, J = 8.4 Hz, 1H, H3), 6.56 (s, 2H, H6), 
3.25 (s, 3H, H11), 2.37 (s, 3H, H8); 13C NMR (151 MHz, DMSO-d6) δ 162.23, 160.05, 
152.14, 150.28, 141.96, 141.91, 139.74, 139.17, 135.96, 133.09, 132.06, 130.76 (2C), 
130.16 (q, J = 29.1 Hz, 1C, C-CF3) 128.25, 127.69, 127.08, 126.21, 124.67, 124.58 (q, J = 




JA066: N-(6-bromo-3-(4-hydroxyphenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)acetamide (12.1) 
Compound 8.3 (114.5 mg, 0.34 mmol, 1.0 Eq) was 
heated in acetic anhydride (0.4 mL) at 100°C for 2 
hours, diluted with Et2O and filtered to afford a 
white solid (30 mg, 23%); m.p. 231.4 – 234.6°C; Rf 
(4% MeOH in DCM) 0.5; 1H NMR (400 MHz, DMSO-
d6) δ 9.86 (s, 1H, H4), 9.76 (s, 1H, H8), 8.18 (d, J = 2.4 
Hz, 1H, H1), 8.00 (dd, J = 8.7, 2.4 Hz, 1H, H2), 7.61 (d, J 
= 8.7 Hz, 1H, H3), 7.10 (d, J = 8.8 Hz, 2H, H6), 6.85 (d, 
J = 8.7 Hz, 2H, H7), 1.87 (s, 3H, H5); 13C NMR (101 MHz, DMSO-d6) δ 161.41, 158.06, 
146.60, 138.10, 130.11, 129.99 (2C), 129.14 (2C), 127.02, 122.18, 119.17, 117.00, 115.77 


















































4-(2Aacetamido-6-bromo-4-oxoquinazolin-3(4H)-yl)phenyl acetate (12.2) 
Off-white solid (97.8 mg, 93%); m.p. 228.0 – 
234.6°C; Rf (5:5 EtOAc:Hexane) 0.47; 1H NMR (400 
MHz, DMSO-d6) δ 8.31 (d, J = 2.3 Hz, 1H, H1), 8.13 
(dd, J = 8.7, 2.3 Hz, 1H, H2), 7.77 (d, J = 8.7 Hz, 1H, 
H3), 7.34 (d, J = 2.7 Hz, 4H, H6, H7), 2.31 (s, 3H, H8), 
2.20 (s, 3H, H5); 13C NMR (101 MHz, DMSO-d6) δ 
171.63, 169.40, 161.21, 151.56, 145.87, 145.21, 
138.62, 132.87, 130.35, 129.56 (2C), 129.40, 
123.44 (2C), 123.35, 121.56, 25.72, 21.32; HPLC-
MS (APCI/ESI): Purity 99%, tR = 4.000 min, m/z [M+H]
+ 
= 415.9, 417.9.  
6.2.8. GENERAL PROCEDURE FOR THE SYNTHESIS OF COMPOUNDS 12.3 – 12.4  
Sodium bisulfate (NaHSO4) (2.0 Eq) was added to a solution of 2-amino-5-
bromobenzamide (1.0 Eq) and the relevant benzaldehyde (1.0 Eq) in DMF (25 Eq). The 
mixture was refluxed at 150 °C for 3 hours and poured into ice-water. The precipitate 
was filtered, washed with water followed by ethanol and dried to form 2-
arylquinazolinones 12.3 – 12.4. 
JA072: 6-bromo-2-phenylquinazolin-4(3H)-one (12.3) 
White crystalline solid (137.9 mg, 69%); m.p. 306.2 – 
310.4°C; Rf (6:4 EtOAc: Hexane) 0.41; 1H NMR (300 
MHz, DMSO-d6) δ 12.68 (s, 1H, H4), 8.23 (d, J = 2.3 Hz, 
1H, H1), 8.18 (dd, J = 8.1, 1.6 Hz, 2H, H5), 7.98 (dd, J = 8.7, 
2.4 Hz, 1H, H2), 7.70 (d, J = 8.7 Hz, 1H, H3), 7.64 – 7.53 
(m, 3H, H6, H7); 13C NMR (101 MHz, DMSO-d6) δ 161.73, 
153.51, 148.18, 137.88, 132.99, 132.08, 130.29, 129.11 
(2C), 128.48, 128.33 (2C), 123.08, 119.38; HPLC-MS (APCI/ESI): Purity >99%, tR = 4.787 
min, m/z [M+H]
+ 









































JA073: 6-bromo-2-(4-hydroxyphenyl)quinazolin-4(3H)-one (12.4) 
Yellow solid (51.3 mg, 17%); m.p. 314.6 – 318.1°C; Rf 
(6:4 EtOAc:Hexane) 0.28; 1H NMR (400 MHz, DMSO-
d6) δ 12.44 (s, 1H, H4), 10.17 (s, 1H, H7), 8.20 (d, J = 
2.4 Hz, 1H, H1), 8.09 (d, J = 8.8 Hz, 2H, H5), 7.93 (dd, J 
= 8.7, 2.4 Hz, 1H, H2), 7.63 (d, J = 8.7 Hz, 1H, H3), 6.90 
(d, J = 8.8 Hz, 2H, H6); 13C NMR (101 MHz, DMSO-d6) 
δ 161.68, 161.24, 153.21, 148.55, 137.74, 130.19 
(2C), 130.05, 128.41, 123.40, 122.66, 118.58, 115.88 
(2C); HPLC-MS (APCI/ESI): Purity >99%, tR = 4.448 min, m/z [M+H]
+ 
= 317.0, 319.0 
(1:1).  
6.3. BIOLOGICAL STUDIES 
6.3.1.  IN VITRO ANTIMYCOBACTERIAL ASSAY 
Antimycobacterial studies were performed by Ronnett Seldon at UCT’s Drug Discovery 
and Development Centre, H3D. The broth microdilution method allows a range of 
antibiotic concentrations to be tested on a single 96-well microtitre plate in order to 
determine the minimum inhibitory concentration (MIC).81,82 Briefly, a 10 ml culture of 
Mycobacterium tuberculosis pMSp12 green fluorescent protein (GFP) strain was grown 
to an optical density (OD600) of 0.6 - 0.7. The culture was then diluted 1:500 in the 
appropriate medium.83 In a 96-well microtitre plate, 50 μl of medium was added to all 
wells from Rows 2-12. The compounds to be tested are added to Row 1 in duplicate, at a 
final concentration of 640 µM. A two-fold serial dilution was prepared, using a 
multichannel pipette, by transferring 50 μl of the liquid in Row 1 to Row 2 and 
aspirating to mix. 50 μl of the liquid in Row 2 was then transferred to Row 3 and 
aspirated, and so on. This procedure is repeated until Row 12 is reached, from which 50 
μl of the liquid was discarded so as to bring the final volume in all wells to 50 μl. 
Controls included media only, 5% DMSO, Rifampicin and Kanamycin. Finally, 50 μl of the 
1:500 diluted M. tuberculosis culture was added to all wells in Rows 2-12. Cells were not 
added to Row 1, as this serves as a contamination control. The microtitre plate was 
sealed in a secondary container and incubated at 37°C with humidifier to prevent 
evaporation of liquid. The lowest concentration of drug that inhibits growth of more 


















scored visually at 7-days and 14-days post inoculation, and digital images captured and 
stored.  
6.3.1.1. 7H9 Media Preparation 
Bacto Middlebrook 7H9 (Difco), glycerol and water were combined and autoclaved for 
15 mins. The solution was cooled to 55 - 60°C and100ml ADC Enrichment Media and 
0.05% Tween 80 were added. Filter sterilize (0.2µM filter) and store at 37°C. 
6.3.1.2. ADC Enrichment Media Preparation 
Sodium chloride, bovine albumin fraction V and D-glucose were dissolved into 1L 
distilled water. Filter sterilize (0.2µM filter) and store at 4°C. 
6.3.1.3. Casitone 7H9-Based Medium (BSA-Free) Preparation 
4.7g Middlebrook 7H9 broth + 900 mL water (double distilled) + 2mL glycerol (add with 
sterile syringe) + 0.5mL Tween 80 (add with 1mL sterile syringe). Stir until dissolved 
and filter sterilize (0.2um filter). Aseptically add 100mL ADC. 
6.3.2. IN VITRO CYTOTOXICITY ASSAY 
Test samples were screened for in vitro cytotoxicity against a mammalian cell-line, 
Chinese Hamster ovarian (CHO) using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromide (MTT) assay at the Division of Clinical Pharmacology, 
University of Cape Town. The MTT-assay is used as a colorimetric assay for cellular 
growth and survival, and compares well with other available assays.84,85 The reduction 
of tetrazolium salt MTT to a formazan salt was used to measure all growth and 
chemosensitivity. The test samples were tested in triplicate on one occasion. 
The test samples were prepared to a 20 mg/ml stock solution in 10% methanol or 10% 
DMSO and were tested as a suspension if not properly dissolved. Test compounds were 
stored at -20ºC until use. Emetine was used as the reference drug in all experiments. The 
initial concentration of each compound was 100 µg/ml, which was serially diluted in 
complete medium with 10-fold dilutions to give 6 concentrations, the lowest being 0.001 
µg/ml. The same dilution technique was applied to the all test samples. The highest 
concentration of solvent to which the cells were exposed to had no measurable effect on 
the cell viability (data not shown). Plates were developed after 44 hours of exposure to 
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the drug by the addition of a solution of MTT. After four hours further incubation at 37, 
the supernatant was removed from the cells via suction and DMSO was added to each 
well to dissolve the reduced dye crystals. Plates were analysed at 540nM wavelength 
using a spectrophotometer to determine the relative amount of formazan in each well. 
 
The 50% inhibitory concentration (IC50) values were obtained from full dose-response 
curves, using a non-linear dose-response curve fitting analysis via GraphPad Prism v.4 
software. 
6.3.3. IN VITRO ANTIPLASMODIAL ASSAY 
In vitro activity against the erythrocytic stages NF54 P. falciparum strains was 
determined using a [3H]-hypoxanthine incorporation assay by Sergio Wittlin at the 
Swiss Tropical and Public Health Institute. Compounds were dissolved in DMSO at 10 
mg/mL and added to parasite cultures incubated in RPMI 1640 medium without 
hypoxanthine, supplemented with HEPES (5.94 g/l), NaHCO3 (2.1 g/l), neomycin (100 
U/mL), AlbumaxR (5 g/l) and washed A+ human red cells at 2.5 % hematocrit (0.3% 
parasitemia). Serial drug dilutions of eleven three-fold dilution steps covering a range 
from 100 to 0.002 μg/mL were prepared. The 96-well plates were incubated in a 
humidified atmosphere at 37 °C; 4 % CO2, 3 % O2 and 93 % N2. After 48 h, 50 μL of 3H-
hypoxanthine (= 0.5 μCi) was added to each well of the plate. The plates were incubated 
for a further 24 h under the same conditions. The plates were then harvested with a 
Betaplate™ cell harvester (Wallac, Zurich, Switzerland), and the red blood cells 
transferred onto a glass fiber filter then washed with distilled water. The dried filters 
were inserted into a plastic foil with 10 ml of scintillation fluid, and counted in a 
Betaplate™ liquid scintillation counter (Wallac, Zurich, Switzerland). IC50 values were 
calculated from sigmoidal inhibition curves by linear regression using Microsoft Excel. 
6.3.4. IN VITRO METABOLIC STABILITY STUDIES 
The metabolic stability of compounds was assessed in mouse, rat and human liver 
microsomes at the pre-clinical pharmacology laboratory at Groote Schuur Hospital. All 
compounds were prepared to a 10 mM stock solution in DMSO. The test compound (1 
μM) was incubated at 37 °C in a solution containing 0.35 mg/ml microsomes (MLM – 
male mouse BALB/c, Xenotech; RLM – male rat IGS, Xenotech or HLM – mixed gender, 
Xenotech) and NADPH (1 mM) in phosphate buffer (100 mM, pH 7.4) for 30 min while 
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shaking. The samples were then prepared by cold-ice acetonitrile precipitation 
containing 0.1μM carbamazepine (internal standard), centrifuged and filtered for LC-MS 
analysis. The incubations were performed in triplicate and three controls (propranolol, 
midazolam and MMV390048) were also included. Results are reported as percentage 
remaining unchanged after 30 min incubation and as predicted half-life using Obach’s 
formula. 
LC-MS/MS analysis was performed on a 4000 Q-TRAP (AB SCIEX) equipment with a 
Turbo V® ion source coupled to an Agilent 1200 Rapid Resolution (600 bar) HPLC 
system. Electron spray ionization mode was used for all synthetic compounds. Analyst 
1.5.1 software was used for instrument control and data acquisition. Metabolic stability 
analysis was performed using a Kinetex PFP column, 2.1 mm × 50 mm, 2.6 μm particles 
(Phenomenex) or a Kinetex C18 column, 2.1 mm × 50 mm, 2.6 μm particles 
(Phenomenex) with gradient of 0.4 ml/min of the mobile phase constituted of 0.1% 
formic acid (A) and 0.1% formic acid in acetonitrile (B) at 40 °C. Sample tray 
temperature was 8 °C and the injection volume used was 2 μL. Multiple reaction 
monitoring (MRM) mode was used for quantification of parent compound before and 
after incubation in liver microsomes. 
6.3.5. HPLC-BASED SOLUBILITY STUDIES 
Kinetic solubility of compounds was performed by Mathew Njoroge at the drug 
discovery and development centre, H3D. Aqueous solubility was measured using the 
DMSO-dry down method, adapted from Zhou et al.69 Briefly, the high and medium 
calibration standards (220µM, 100µM) in duplicate as well as the samples (200µM) in 
triplicate were added to a 96-well plate, from a 10mM stock solution in DMSO. DMSO 
was then evaporated in a MiVac sample concentrator (SP Scientific, Cape Town, South 
Africa) operated at full vacuum, 37°C, for 2 hours. DMSO was then added to the 
standards and after vortexing the plate, the high standard was used to prepare a low 
(11µM) calibration standard in DMSO. Phosphate buffered saline (pH 7.4) was added to 
the sample wells and the plate was incubated for 24hrs at 25°C with shaking. The plate 
was then centrifuged at 2500g for 30min and the supernatants transferred to another 
plate for analysis. Aqueous solubility was determined from UV peak areas of the samples 
relative to the standards using best-fit calibration curves in Microsoft Excel 2013. 
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HPLC-DAD analysis was performed using an Agilent 1200 Rapid Resolution HPLC, 
coupled with an Agilent 1200 diode array detector (ABSciex, Johannesburg, South 
Africa). For elution, 0.1% formic acid in water and 0.1% formic acid acetonitrile were 
used as mobile phases A and B respectively. A Kinetex C18 (50mm x 2.1 mm), packed 
with 2.6 μM fused-core particles (Separations, Johannesburg, South Africa) was used for 
the chromatography. Agilent Chemstation for used for instrument control and data 
processing. 
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